



(11) **EP 2 160 464 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**21.05.2014 Bulletin 2014/21**

(51) Int Cl.:  
**C12N 15/11 (2006.01) C12N 15/87 (2006.01)**

(21) Application number: **08756546.1**

(86) International application number:  
**PCT/US2008/065366**

(22) Date of filing: **30.05.2008**

(87) International publication number:  
**WO 2008/151049 (11.12.2008 Gazette 2008/50)**

(54) **NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS**

NUKLEINSÄURE-FUNKTIONALISIERTE NANOPARTIKEL FÜR THERAPEUTISCHE ANWENDUNGEN

NANOPARTICULES FONCTIONNALISÉES PAR DES ACIDES NUCLÉIQUES POUR DES APPLICATIONS THÉRAPEUTIQUES

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR**

(30) Priority: **30.05.2007 US 940886 P**  
**05.11.2007 US 985462 P**

(43) Date of publication of application:  
**10.03.2010 Bulletin 2010/10**

(73) Proprietor: **Northwestern University**  
**Evanston, IL 60208 (US)**

(72) Inventors:  
• **MIRKIN, Chad A.**  
**Wilmette, IL 60091 (US)**  
• **GILJOHANN, David A.**  
**Chicago, IL 60626 (US)**  
• **SEFEROS, Dwight**  
**Evanston, IL 60202 (US)**  
• **PATEL, Pinal C.**  
**Chicago, IL 60626 (US)**

(74) Representative: **Mallalieu, Catherine Louise**  
**D Young & Co LLP**  
**120 Holborn**  
**London EC1N 2DY (GB)**

(56) References cited:  
**WO-A-2006/012695 WO-A1-2006/138145**

- **CHITHRANI B DEVIKA ET AL: "Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells." NANO LETTERS APR 2006, vol. 6, no. 4, April 2006 (2006-04), pages 662-668, XP002493714 ISSN: 1530-6984**
- **YIN WIN K ET AL: "Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 15, 1 May 2005 (2005-05-01), pages 2713-2722, XP004673437 ISSN: 0142-9612**
- **ROSI NATHANIEL L ET AL: "Oligonucleotide-modified gold nanoparticles for intracellular gene regulation" SCIENCE (NEW YORK, N.Y.) 19 MAY 2006,, vol. 312, no. 5776, 19 May 2006 (2006-05-19), pages 1027-1030, XP002489177**
- **GILJOHANN DAVID A ET AL: "Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles." NANO LETTERS DEC 2007, vol. 7, no. 12, December 2007 (2007-12), pages 3818-3821, XP002493715 ISSN: 1530-6984**

**EP 2 160 464 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

**[0001]** Nucleic acid-based methods for controlling gene expression have significantly impacted research involving gene pathways and function (Patil, et al., AAPS Jour, 7, E61 (2005), McManus, et al., Nat. Rev. Genet. 3,737 (2002), Lebedeva, et al., Annu. Rev. Pharmacol. Toxicol. 41, 403 (2001)). In addition, antisense therapies are potentially powerful candidates for clinical treatments of various ailments, including cancer, HIV/ AIDS, and other diseases (Patil, et al., supra., Jason, et al., Toxic. And Appl. Pharm. 201, 66 (2004)). One antisense agent, Vitravene™, is currently used to treat retinitis in AIDS patients (Patil, et al., supra.). In conventional antisense approaches, oligonucleotides designed to hybridize with target mRNA sequences are delivered to a cell in a variety of ways. This hybridization leads to a down-regulation in the expression of the corresponding translated proteins. While the potential of antisense oligodeoxyonucleotides (ASODNs) was recognized over twenty years ago (Stephenson, et al., Proc. Nat. Acad. Sci. U.S.A. 75, 285 (1978) Zamecnik, et al., Proc. Nat. Acad. Sci. U.S.A. 75,280 (1978)), their development into viable therapeutic systems has faced challenges with regard to stable transfection and entry into diverse cell types, toxicity, and low efficacy. To address these fundamental barriers, various transfection agents have been developed to shuttle nucleic acids into cells. These include cationic lipids and polymers, modified viruses, dendrimers, liposomes, and nanoparticles (Patil, et al., supra., Jason, et al., supra., Bharali et al., Proc. Nat. Acad. Sci. U.S.A. 102, 11539 (2005), Bielinska, et al., Bioconjugate Chem. 10, 843 (1999)). Along with developments in delivery platforms, efforts have focused on developing nucleic acid analogs and investigating their potential as ASODNs.

**[0002]** These include ODNs having phosphorothioate- or morpholino-modified backbones and peptide nucleic acids (PNAs) (De Mesmaeker, et al., Acc. Chem. Res. 28, 366 (1995), Myers, et al., Org. Lett. 5, 2695 (2003)). In some cases, the modified ASODNs provide enhanced stability in the presence of cellular endo- and exonucleases and stronger binding affinity with complementary sequences. Most antisense experiments use modified ASODNs in combination with a delivery mechanism in order to achieve maximum efficacy. While many combinations of carriers and modified ASODNs show promise, no single system has emerged that is vastly superior to others. Typical methods such as using phosphorothioate ASODNs complexed with cationic lipid carriers are often only useful in serum-free transfections and are semi-toxic to certain cell types, thus limiting their general utility and their potential in therapeutics.

**[0003]** Gold nanoparticles have proven to be extremely useful for diagnostic and other applications. Detailed studies of gold nanoparticles surface-functionalized with both nucleic acids and proteins demonstrate a number of unique and highly useful characteristics of such structures. For instance, oligonucleotides attached to gold nanoparticles bind more strongly and more specifically to complementary oligonucleotides than do oligonucleotides that are not attached to gold nanoparticles. These observations are, in general, associated with the surface density of the oligonucleotide on the nanoparticle (i.e., surface density). The change in hybridization of the oligonucleotide (bound to a nanoparticle) to a target polynucleotide is reflected in an increase in melting temperature ( $T_m$ ), a sharper melting profile, and/or a decrease in the dissociation constant ( $K_{diss}$ ) of the resulting hybridization complex compare to hybridization of the free oligonucleotide and the target polynucleotide. These binding events can furthermore alter the physical, electronic and optical properties of the gold nanoparticles in useful ways such as producing characteristic spectral shifts upon the specific binding of an attached oligonucleotide to its complement. Carbohydrates, lipids and proteins such as antibodies can also be attached to gold nanoparticles either individually or in combination.

**[0004]** To improve upon current methods, there exists a need in the art for an ideal antisense system that would feature high uptake efficiencies across many cell types, high intracellular stability, and a strong binding affinity to target mRNA, while maintaining a very low toxicity to either non-targeted cells when the application requires cell killing, or toward the targeted cells when gene manipulation is desired for other applications.

**[0005]** In an aspect of the invention, a method of modulating cellular uptake of a first functionalized nanoparticle compared to a second functionalized nanoparticle is provided comprising the step of modulating packing density of an oligonucleotide functionalized on the first nanoparticle, wherein a higher packing density results in increased cellular uptake of the functionalized nanoparticle compared to the second nanoparticle functionalized at a lower packing density.

**[0006]** In various embodiments, the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 1 oligonucleotide per nanoparticle. In alternative embodiments, the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 5 oligonucleotides per nanoparticle, by at least 10 oligonucleotides per nanoparticle, by at least 20 oligonucleotides per nanoparticle, by at least 40 oligonucleotides per nanoparticle, by at least 60 oligonucleotides per nanoparticle, or by at least 80 oligonucleotides per nanoparticle. In still other embodiments, uptake of the first functionalized nanoparticle is increased by at least 50% compared to the second nanoparticle, or by at least 100% compared to the second nanoparticle.

**[0007]** We describe methods for modulating effectiveness of a therapeutic agent comprising the step of administering said therapeutic agent concomitantly with an oligonucleotide-functionalized nanoparticle, wherein said oligonucleotide-functionalized nanoparticle comprises an oligonucleotide comprising a sequence that modulates the effectiveness of said therapeutic agent.

**[0008]** We describe that in the methods, cellular localization of the therapeutic agent is controlled by the oligonucleotide-

functionalized nanoparticle and in other methods, the oligonucleotide sequence is a chemosensitizing antisense sequence. In certain methods we describe the chemosensitizing antisense sequence increases the toxicity of the therapeutic agent.

5 [0009] Methods are also described for modulating effectiveness of a therapeutic agent comprising the step of administering said therapeutic agent concomitantly with a oligonucleotide-functionalized nanoparticle, wherein concentration of the oligonucleotide-functionalized nanoparticle modulates the effectiveness of said therapeutic agent.

[0010] Additional methods are described for specifically delivering a therapeutic agent comprising the step of administering said therapeutic agent concomitantly with a oligonucleotide-functionalized nanoparticle, wherein the oligonucleotide-functionalized nanoparticle comprises a targeting agent that specifically delivers said therapeutic agent.

10 [0011] Methods of inhibiting expression of a gene product are described comprising the step of hybridizing a polynucleotide encoding the gene product with one or more oligonucleotides complementary to all or a portion of the polynucleotide, the oligonucleotide being bound to a nanoparticle, wherein hybridizing between the polynucleotide and the oligonucleotide occurs over a length of the polynucleotide with a degree of complementarity sufficient to inhibit expression of the gene product. The oligonucleotide may be covalently bound to the nanoparticle. In various other methods, the  
15 oligonucleotide bound to the nanoparticle and the polynucleotide exhibit at least one property selected from the group consisting of an increased melting temperature ( $T_m$ ), a sharper melting profile, and an increased association (or decreased dissociation) binding constant for hybridization, compared to the oligonucleotide not bound to the nanoparticle and the polynucleotide. In another method, the oligonucleotide is bound to the nanoparticle at a surface density high enough to increase cooperative hybridization to the polynucleotide compared to the same oligonucleotide when not bound to said  
20 nanoparticle.

[0012] In various methods, expression of the gene product is inhibited in vivo and expression of the gene product is inhibited in vitro. Methods are also described wherein the oligonucleotide is bound to the nanoparticle through one or more sulfur linkages.

25 [0013] In various other methods, the oligonucleotide is bound to the nanoparticle through a 5' linkage and/or the oligonucleotide is bound to the nanoparticle through a 3' linkage. In another method, one or more additional oligonucleotides are attached, indirectly, to a functionalized nanoparticle by hybridization of the additional oligonucleotide to an oligonucleotide functionalized on the nanoparticle surface. In yet another method, one or more additional oligonucleotides are attached to an oligonucleotide, functionalized on the nanoparticle surface, through an internal linkage. Methods described use of an oligonucleotide which comprises a tandem repeat of identical nucleotide sequences, and in various  
30 aspects, the tandem repeat comprises two identical nucleotide sequences, three identical nucleotide sequences, four identical nucleotide sequences, five identical nucleotide sequences, or five or more identical nucleotide sequences. In certain aspects, the identical nucleotide sequences in the tandem repeat are separated by a nucleotide spacer between each identical sequence.

35 [0014] Consistent with the above described, methods are also described wherein two or more identical oligonucleotide sequences and at least one distinct oligonucleotide sequence are bound to the same nanoparticle, either individually bound to the nanoparticle or arranged in a tandem array as described above, with or without spacers as described herein.

[0015] In methods described the target polynucleotide is a mRNA encoding the gene product and translation of the gene product is inhibited. Methods are also described wherein the target polynucleotide is DNA in a gene encoding the gene product and transcription of the gene product is inhibited. In variations of this method, the DNA encodes the gene  
40 product or the DNA is complementary to a coding region for the gene product. Alternatively, the target DNA is a region or sequence which is necessary for DNA replication. Additional targets contemplated by the methods include without limitation microRNA (miRNA), small interfering RNA (siRNA), premiRNA, small hairpin RNA (shRNA), transfer RNA (tRNA), proteins, viruses and small molecules.

45 [0016] Methods are also described wherein the target polynucleotide is a bacterial polynucleotide. In this method, the bacterial polynucleotide is bacterial genomic DNA or RNA transcribed from bacterial genomic DNA.

[0017] Methods are also described wherein the target polynucleotide is a viral polynucleotide. In this method, the viral polynucleotide is viral genomic RNA, the viral polynucleotide is viral genomic DNA, or the viral polynucleotide is RNA transcribed from viral genomic DNA. In another method, the viral polynucleotide is a segment of a viral genome that has been integrated into the genome of another organism.

50 [0018] In various other methods described, expression of the gene product is inhibited by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% compared to expression in the absence of the oligonucleotide.

55 [0019] In still other methods described, the oligonucleotide is bound to the nanoparticle at a surface density of 0.3 pmol/cm<sup>2</sup>, at least about 0.6 pmol/cm<sup>2</sup>, at least about 0.9 pmol/cm<sup>2</sup>, at least about 1.2 pmol/cm<sup>2</sup>, at least about 1.5 pmol/cm<sup>2</sup>, at least about 1.8 pmol/cm<sup>2</sup>, at least about 2.1 pmol/cm<sup>2</sup>, at least about 2.4 pmol/cm<sup>2</sup>, at least about 2.7 pmol/cm<sup>2</sup>, at least about 3.0 pmol/cm<sup>2</sup>, at least about 3.3 pmol/cm<sup>2</sup>, at least about 3.6 pmol/cm<sup>2</sup>, at least about 3.9 pmol/cm<sup>2</sup>, at least about 4.2 pmol/cm<sup>2</sup>, at least about 4.5 pmol/cm<sup>2</sup>, at least about 4.8 pmol/cm<sup>2</sup>, at least about 5.1

pmol/cm<sup>2</sup>, at least about 5.4 pmol/cm<sup>2</sup>, at least about 5.7 pmol/cm<sup>2</sup>, at least about 6.0 pmol/cm<sup>2</sup>, at least about 6.3 pmol/cm<sup>2</sup>, at least about 6.6 pmol/cm<sup>2</sup>, at least about 6.9 pmol/cm<sup>2</sup>, at least about 7.2 pmol/cm<sup>2</sup>, at least about 7.5 pmol/cm<sup>2</sup>, at least about 7.8 pmol/cm<sup>2</sup>, at least about 8.1 pmol/cm<sup>2</sup>, at least about 8.4 pmol/cm<sup>2</sup>, at least about 8.7 pmol/cm<sup>2</sup>, at least about 9.0 pmol/cm<sup>2</sup>, at least about 9.3 pmol/cm<sup>2</sup>, at least about 9.6 pmol/cm<sup>2</sup>, at least about 9.9 pmol/cm<sup>2</sup>, at least 10 pmol/cm<sup>2</sup>, at least 15 pmol/cm<sup>2</sup>, at least 20 pmol/cm<sup>2</sup>, at least 10 pmol/cm<sup>2</sup>, at least 25 pmol/cm<sup>2</sup>, at least 30 pmol/cm<sup>2</sup>, at least 35 pmol/cm<sup>2</sup>, at least 40 pmol/cm<sup>2</sup>, at least 45 pmol/cm<sup>2</sup>, at least 50 pmol/cm<sup>2</sup>, at least 55 pmol/cm<sup>2</sup>, at least 60 pmol/cm<sup>2</sup>, at least 65 pmol/cm<sup>2</sup>, at least 70 pmol/cm<sup>2</sup>, or at least 75 pmol/cm<sup>2</sup>.

[0020] Methods include those wherein expression of the targeted gene product is associated with a disease state.

[0021] Methods also include those wherein the nanoparticle is optionally labeled.

[0022] Methods also include those wherein the nanoparticle further comprises a targeting molecule.

[0023] In various aspects of the methods, packing density of the oligonucleotides on the surface of the nanoparticle is sufficient to result in cooperative behavior between the nanoparticles.

[0024] According to the invention, packing density for the oligonucleotides on the surface of the nanoparticle is sufficient to enhance cellular uptake.

[0025] Methods are also described wherein the target polynucleotide is an inhibitory RNA (including, without limitation, siRNA) that performs a regulatory function, the oligonucleotide is complementary to a regulatory region of the polynucleotide, the oligonucleotide is released from the nanoparticle after the nanoparticle enters a cell, and/or the nanoparticle includes a targeting moiety.

## DESCRIPTION OF THE DRAWINGS

### [0026]

Figure 1. Cellular uptake of ASNPs. Analysis of ASNPs in three different cell types (HeLa, C166, A549) shows that the number of ASNPs per cell is dependent on initial particle concentration and cell type.

Figure 2. A) Characterization of oligonucleotide loading on OEG (oligo(ethylene glycol)):DNA particles. B) Uptake as a function of the number of oligonucleotides per ASNP in A549 cells. C) Au NPs functionalized with OEG show comparatively little uptake (A549 cells) even at high concentration additions.

Figure 3. Plots of cell viability as a function of nanoparticle concentration of dox-treated cell cultures. Dox-treated controls are circled. The lines are drawn as a guide to the eye.

[0027] Gold nanoparticles exhibit a variety of unique optical, electronic, and catalytic properties (Daniel, et al., Chem. Rev. 104, 293 (2004)), and owing to their affinity for biomolecules, they have been used extensively in immunostaining (Baudhuin, et al., Colloidal Gold: Principles, Methods, and Applications 2, 1 (1989)), as intracellular targeting agents (Tkachenko et al., Bioconjugate Chem. 15, 482 (2004)), and as non-viral vectors for DNA delivery (Thomas, et al., Proc. Nat. Acad. Sci. 100, 9138 (2003), Sundaram, et al., Nucl. Acids Res. 24, 1375 (1999), Sandhu, et al., Bioconjugate Chem. 13, 3 (2002), Sullivan, et al., Gene Therapy 10, 1882 (2003), Jen et al., Langmuir 20, 1369 (2004)). Developments in the last decade have shown that gold nanoparticles chemically functionalized with alkythiol-terminated oligonucleotides (Mirkin, et al., Nature 382, 607 (1996)) are highly stable in saline solutions and bind complementary nucleic acids in a very selective and cooperative manner, resulting in equilibrium association constants that can be more than two orders of magnitude greater than those observed for unmodified oligonucleotides and their complements (Lytton-Jean, et al., J Am. Chem. Soc. 127, 12754 (2005)). These unique properties have made oligonucleotide-functionalized gold nanoparticles the centerpiece of several highly sensitive and selective assays for biomolecule detection (Rosi, et al., Chem. Rev. 105, 1547 (2005), Elghanian, et al., Science 277; 1078 (1997), Nam, et al., Science 301, 1884 (2003), He et al., J Am. Chem. Soc. 122, 9071 (2000), Maxwell, et al., J Am. Chem. Soc. 124, 9606 (2002)). Due to their demonstrated stability and enhanced binding properties, it was hypothesized that these particles could potentially be used as efficient scavengers of intracellular DNA or RNA. Accordingly, methods are provided wherein oligonucleotide-functionalized gold nanoparticles are intrinsically new antisense agents that rely on the ensemble properties of the nanoparticle-oligonucleotide conjugate.

[0028] As is described in US Patent Application 20030147966 and elsewhere, it is also well known in the art that gold nanoparticles can pass through cell and, under suitable conditions, nuclear membranes, thus providing a means for labeling cells and for delivering materials into cells and cell nuclei. The utility of these previous methods is, however, limited by the relative instability of surface modified gold nanoparticles. These limitations have been partially addressed by means such as the inclusion of phosphorothioate linkages in the oligonucleotides attached to the nanoparticles in order to retard the degradation of the oligonucleotides by nucleases and by encapsulating the modified nanoparticles in proteinaceous and other protective sheaths.

**[0029]** As used herein, a "therapeutic agent" is any agent from which a therapeutic benefit is or can be derived from its administration or from which a therapeutic benefit would be expected from its administration regardless of whether the benefit is realized.

**[0030]** The utility of the methods provided is demonstrated by the use of the oligonucleotide-modified gold nanoparticles for the *in vivo* silencing of the expression of a cellular gene by suppressing the translation of the mRNA produced by that gene. In this application, the increase in the binding constant for gold nanoparticles to their complementary sequences by as much as 100X that results from the present invention is, in contrast to the prior art, such that the replication of the genomic sequence(s) bound to the gold-nanoparticle is completely prevented. This ability to silence gene expression can be used in the treatment of disease states that are characterized by the expression of proteins that are aberrant in structure or location. In certain aspects, the methods provided are used for the delivery of expressible genes, including double stranded polynucleotides, into cells in a manner that avoids the well known limitations of retroviral transduction and mechanical methods such as electroporation or "gene guns" that are employed for similar purposes. The utility of these methods can be further enhanced by modifying the gold nanoparticle such that both oligonucleotides and selective binding agents such as antibodies, lectins or cell-specific recognition elements such as RGD peptides or certain carbohydrates or glycoproteins are attached thereto so long as the oligonucleotide surface density is not reduced below the critical threshold level for stability. These cell-specific recognition elements permit the targeting of the oligonucleotide-modified gold nanoparticle to particular cells or cell types with the corresponding improvement in the efficacy of the treatment. In other aspects, the gold nanoparticles are surface functionalized with imaging contrast agents and, in various embodiments have magnetic cores that impart further advantages with respect to imaging and selective cellular targeting. When functionalized nanoparticles also include a label or imaging agent, entry into a target cell type can be quantitated by visualization or by direct or indirect detection. Quantitation of cell entry permits a precise determination of the number of nanoparticle entering a cell, which in turn allows for precise determination of appropriate dosages for *in vivo* administration. In still other aspects, the gold nanoparticles are additionally functionalized with known small molecule therapeutic agents that augment the therapeutic efficacy of co-delivered species on the surface of the nanoparticles (e.g. DNA, proteins, carbohydrates, etc.).

**[0031]** In other aspects, methods are provided wherein the effects of a therapeutic agent are modulated comprising the step of administering the therapeutic agent concomitantly with an oligonucleotide-functionalized nanoparticle, wherein the oligonucleotide associates with the therapeutic agent through any mode of interaction thereby modulating the effectiveness of the therapeutic agent. In one aspect, methods are provided wherein the effects of a therapeutic agent are modulated comprising the step of administering said therapeutic agent and said oligonucleotide-functionalized nanoparticle sequentially, wherein either is administered first in the sequence. In another aspect, methods are provided wherein the effects of a therapeutic agent are modulated comprising the step of administering said therapeutic agent and said oligonucleotide-functionalized nanoparticle sequentially, wherein either the therapeutic agent or the oligonucleotide functionalized nanoparticle is administered, and after a period of time passes, this first administration is followed by administration of either the therapeutic agent or the oligonucleotide functionalized nanoparticle, whichever was not administered first. In various aspects, the period of time is at least about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 4, minutes, at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9 minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at least about 25 minutes, at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 10 hours, at least about 15 hours, at least about 18 hours, at least about 24 hours, at least about 36 hours, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days at least about 7 days , at least about 10 days, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months or more.

**[0032]** In still other aspects, the effect of the therapeutic agent is modulated by administering a different amount of a functionalized nanoparticle relative to a previously administered amount to control the activity of a therapeutic agent. In some aspects, the amount is increased or decreased by at least 10%. In other aspects, the amount is increased or decreased by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2-fold, at least 4-fold, at least 6-fold, at least 8-fold, at least 10-fold, at least 20-fold, at least 50 fold, at least 100-fold or more.

**[0033]** In various aspects, the effect of the therapeutic agent is modulated by administering a different amount of a therapeutic agent relative to a previously administered amount to offset activity of a functionalized nanoparticle. In some aspects, the amount of the therapeutic agent that is administered is increased or decreased by at least 10%. In other aspects, the amount is increased or decreased by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 2-fold, at least 4-fold, at least 6-fold, at least 8-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold or more.

**[0034]** In some aspects, the effectiveness of the therapeutic agent is altered by at least 10%, or at least 15%, or at least 20%, or at least 25%, or at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, at least

80%, at least 90%, at least 95%, at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold or more compared to effectiveness of the therapeutic agent in the absence of the oligonucleotide-functionalized nanoparticle, regardless of the number of times either the therapeutic agent is administered and/or the number of times the oligonucleotide-functionalized nanoparticle is administered.

5 [0035] In various aspects, the effectiveness of the therapeutic agent is altered as a result of the oligonucleotide-functionalized nanoparticle causing localization of the therapeutic agent to the extent that effectiveness of the therapeutic agent is altered. In one aspect and without being bound to a mechanism, it is contemplated that binding or association of the therapeutic agent to or with an oligonucleotide-functionalized nanoparticle prevents the therapeutic agent from reaching its target area thereby decreasing effectiveness of the therapeutic agent. One of ordinary skill in the art will recognize that oligonucleotide-functionalized nanoparticles can be modified to localize the nanoparticle and thus in turn localize the therapeutic agent. Such modifications include, but are not limited to, intracellular localization and tissue-specific localization.

10 [0036] In another aspect, methods are provided wherein an antisense sequence functionalized on a nanoparticle is administered concomitantly or sequentially with a therapeutic agent whereby the antisense functionalized nanoparticle increases the effectiveness of the therapeutic agent. In this aspect and without being bound to a mechanism, the antisense sequence may bind not only to the therapeutic agent but also to a target mRNA of interest. In one aspect of this method, administration of the antisense functionalized nanoparticle enhances the effectiveness of the therapeutic agent, in another aspect administration of the antisense functionalized nanoparticle decrease the effectiveness of the therapeutic agent.

15 [0037] Accordingly, in various aspects of the invention methods are provided wherein an oligonucleotide-functionalized nanoparticle comprises a targeting agent directed to a non-target cell or tissue that decreases the effectiveness of a therapeutic agent specifically in said non-target cell or tissue by titrating said therapeutic agent specifically in said non-target cell or tissue.

20 [0038] In another aspect, a therapeutic agent is administered either concomitantly or sequentially with an antisense oligonucleotide-functionalized nanoparticle comprising a targeting agent direct to a target cell or tissue in combination with an oligonucleotide-functionalized nanoparticle comprising a targeting agent directed to a non-target cell or tissue, wherein the effectiveness of the therapeutic agent is increased in a target cell or tissue and decreased in a non-target cell or tissue. In aspects of the invention, antisense oligonucleotides may be selected that either increase or decrease the effectiveness of a therapeutic agent.

25 [0039] In other aspects, nanoparticles may be functionalized with polypeptides that can bind to a therapeutic agent to modulate said therapeutic agent's effectiveness. In some aspects, said polypeptide-functionalized nanoparticle may additionally contain a targeting agent. In another aspect, a method is provided wherein a therapeutic agent is administered either concomitantly or sequentially with two or more groups of functionalized nanoparticles wherein each group comprises a different targeting agent.

30 [0040] In still other aspects, methods are provided wherein multiple different therapeutic agents are used in combination with multiple nanoparticles functionalized with different oligonucleotides. In one aspect, the oligonucleotide-functionalized nanoparticles additionally include a targeting agent attached thereto.

35 [0041] Thus, methods of inhibiting expression of a gene product are provided comprising the step of hybridizing a polynucleotide encoding the gene product with one or more oligonucleotides complementary to all or a portion of the polynucleotide, the oligonucleotide being bound to a nanoparticle, wherein hybridizing between the polynucleotide and the oligonucleotide occurs over a length of the polynucleotide with a degree of complementarity sufficient to inhibit expression of the gene product. Methods wherein expression of the gene product is inhibited *in vivo* and/or *in vitro* are contemplated.

40 [0042] In another aspect, methods are provided to introduce a mutation in a polynucleotide of a cell comprising the step of contacting the cell with an oligonucleotide bound to a nanoparticle, wherein the oligonucleotide has a sequence that includes one or more bases that differ from the sequence of a target polynucleotide in the cell, and wherein the oligonucleotide is otherwise sufficiently complementary to the target polynucleotide to permit hybridization to the target polynucleotide, and further wherein hybridization allows for cross-over and/or recombination with the target polynucleotide during replication of the target polynucleotide. In one aspect, replication of the target polynucleotide occurs during cell division. In another aspect, replication of the target polynucleotide occurs during replication of the target polynucleotide which is extra-chromosomal. In various embodiments, the mutation which is introduced results in inhibited expression of a gene product encoded by the target polynucleotide, whether through modification of transcriptional and/or translational regulatory sequences in the target polynucleotide, or the mutation corrects one or more bases sequences in the target polynucleotide such that the gene product encoded by the target polynucleotide is expressed having the correct, or "naturally-occurring" amino acid sequence, and/or transcriptional and/or translational regulatory elements.

## 55 NANOPARTICLES

[0043] In general, nanoparticles contemplated include any compound or substance with a high loading capacity for

an oligonucleotide as described herein, including for example and without limitation, a metal, a semiconductor, and an insulator particle compositions, and a dendrimer (organic versus inorganic).

**[0044]** Thus, nanoparticles are contemplated which comprise a variety of inorganic materials including, but not limited to, metals, semi-conductor materials or ceramics as described in US patent application No 20030147966. For example, metal-based nanoparticles include those described herein. Ceramic nanoparticle materials include, but are not limited to, brushite, tricalcium phosphate, alumina, silica, and zirconia. Organic materials from which nanoparticles are produced include carbon. Nanoparticle polymers include polystyrene, silicone rubber, polycarbonate, polyurethanes, polypropylenes, polymethylmethacrylate, polyvinyl chloride, polyesters, polyethers, and polyethylene. Biodegradable, biopolymer (e.g. polypeptides such as BSA, polysaccharides, etc.), other biological materials (e.g. carbohydrates), and/or polymeric compounds are also contemplated for use in producing nanoparticles.

**[0045]** In one embodiment, the nanoparticle is metallic, and in various aspects, the nanoparticle is a colloidal metal. Thus, in various embodiments, nanoparticles useful in the practice of the methods include metal (including for example and without limitation, gold, silver, platinum, aluminum, palladium, copper, cobalt, indium, nickel, or any other metal amenable to nanoparticle formation), semiconductor (including for example and without limitation, CdSe, CdS, and CdS or CdSe coated with ZnS) and magnetic (for example., ferromagnetite) colloidal materials. Other nanoparticles useful in the practice of the invention include, also without limitation, ZnS, ZnO, Ti, TiO<sub>2</sub>, Sn, SnO<sub>2</sub>, Si, SiO<sub>2</sub>, Fe, Fe<sup>+4</sup>, Ag, Cu, Ni, Al, steel, cobalt-chrome alloys, Cd, titanium alloys, AgI, AgBr, HgI<sub>2</sub>, PbS, PbSe, ZnTe, CdTe, In<sub>2</sub>S<sub>3</sub>, In<sub>2</sub>Se<sub>3</sub>, Cd<sub>3</sub>P<sub>2</sub>, Cd<sub>3</sub>As<sub>2</sub>, InAs, and GaAs. Methods of making ZnS, ZnO, TiO<sub>2</sub>, AgI, AgBr, HgI<sub>2</sub>, PbS, PbSe, ZnTe, CdTe, In<sub>2</sub>S<sub>3</sub>, In<sub>2</sub>Se<sub>3</sub>, Cd<sub>3</sub>P<sub>2</sub>, Cd<sub>3</sub>As<sub>2</sub>, InAs, and GaAs nanoparticles are also known in the art. See, e.g., Weller, *Angew. Chem. Int. Ed. Engl.*, 32, 41 (1993); Henglein, *Top. Curr. Chem.*, 143, 113 (1988); Henglein, *Chem. Rev.*, 89, 1861 (1989); Brus, *Appl. Phys. A.*, 53, 465 (1991); Bahnemann, in *Photochemical Conversion and Storage of Solar Energy* (eds. Pelizzetti and Schiavello 1991), page 251; Wang and Herron, *J. Phys. Chem.*, 95, 525 (1991); Olshavsky, et al., *J. Am. Chem. Soc.*, 112, 9438 (1990); Ushida et al., *J. Phys. Chem.*, 95, 5382 (1992).

**[0046]** In practice, methods of inhibiting gene expression are provided using any suitable particle having oligonucleotides attached thereto that are in general suitable for use in detection assays known in the art to the extent and do not interfere with complex formation, i.e., hybridization to a target polynucleotide. The size, shape and chemical composition of the particles contribute to the properties of the resulting oligonucleotide-functionalized nanoparticle. These properties include for example, optical properties, optoelectronic properties, electrochemical properties, electronic properties, stability in various solutions, magnetic properties, and pore and channel size variation. The use of mixtures of particles having different sizes, shapes and/or chemical compositions, as well as the use of nanoparticles having uniform sizes, shapes and chemical composition, is contemplated. Examples of suitable particles include, without limitation, nanoparticles particles, aggregate particles, isotropic (such as spherical particles) and anisotropic particles (such as non-spherical rods, tetrahedral, prisms) and core-shell particles such as the ones described in U.S. patent application Ser. No. 10/034,451, filed Dec. 28, 2002 and International application no. PCT/US01/50825, filed Dec. 28, 2002, the disclosures of which are incorporated by reference in their entirety.

**[0047]** Methods of making metal, semiconductor and magnetic nanoparticles are well-known in the art. See, for example, Schmid, G. (ed.) *Clusters and Colloids* (VCH, Weinheim, 1994); Hayat, M. A. (ed.) *Colloidal Gold: Principles, Methods, and Applications* (Academic Press, San Diego, 1991); Massart, R., *IEEE Transactions On Magnetics*, 17, 1247 (1981); Ahmadi, T. S. et al., *Science*, 272, 1924 (1996); Henglein, A. et al., *J. Phys. Chem.*, 99, 14129 (1995); Curtis, A. C., et al., *Angew. Chem. Int. Ed. Engl.*, 27, 1530 (1988). Preparation of polyalkylcyanoacrylate nanoparticles prepared is described in Fattal, et al., *J. Controlled Release* (1998) 53: 137-143 and US Patent No. 4,489,055. Methods for making nanoparticles comprising poly(D-glucaramidoamine)s are described in Liu, et al., *J. Am. Chem. Soc.* (2004) 126:7422-7423. Preparation of nanoparticles comprising polymerized methylmethacrylate (MMA) is described in Ton-delli, et al., *Nucl. Acids Res.* (1998) 26:5425-5431, and preparation of dendrimer nanoparticles is described in, for example Kukowska-Latallo, et al., *Proc. Natl. Acad. Sci. USA* (1996) 93:4897-4902 (Starburst polyamidoamine dendrimers)

**[0048]** Suitable nanoparticles are also commercially available from, for example, Ted Pella, Inc. (gold), Amersham Corporation (gold) and Nanoprobes, Inc. (gold).

**[0049]** Also as described in US patent application No 20030147966, nanoparticles comprising materials described herein are available commercially or they can be produced from progressive nucleation in solution (e.g., by colloid reaction), or by various physical and chemical vapor deposition processes, such as sputter deposition. See, e.g., HaVashi, (1987) *Vac. Sci. Technol.* July/August 1987, A5(4):1375-84; Hayashi, (1987) *Physics Today*, December 1987, pp. 44-60; *MRS Bulletin*, January 1990, pgs. 16-47.

**[0050]** As further described in US patent application No 20030147966, nanoparticles contemplated are produced using HAuCl<sub>4</sub> and a citrate-reducing agent, using methods known in the art. See, e.g., Marinakos et al., (1999) *Adv. Mater.* 11: 34-37; Marinakos et al., (1998) *Chem. Mater.* 10: 1214-19; Enustun & Turkevich, (1963) *J. Am. Chem. Soc.* 85: 3317. Tin oxide nanoparticles having a dispersed aggregate particle size of about 140 nm are available commercially from Vacuum Metallurgical Co., Ltd. of Chiba, Japan. Other commercially available nanoparticles of various compositions

and size ranges are available, for example, from Vector Laboratories, Inc. of Burlingame, Calif.

#### NANOPARTICLE SIZE

5 **[0051]** In various aspects, methods provided include those utilizing nanoparticles which range in size from about 1 nm to about 250 nm in mean diameter, about 1 nm to about 240 nm in mean diameter, about 1 nm to about 230 nm in mean diameter, about 1 nm to about 220 nm in mean diameter, about 1 nm to about 210 nm in mean diameter, about 1 nm to about 200 nm in mean diameter, about 1 nm to about 190 nm in mean diameter, about 1 nm to about 180 nm in mean diameter, about 1 nm to about 170 nm in mean diameter, about 1 nm to about 160 nm in mean diameter, about 1 nm to about 150 nm in mean diameter, about 1 nm to about 140 nm in mean diameter, about 1 nm to about 130 nm in mean diameter, about 1 nm to about 120 nm in mean diameter, about 1 nm to about 110 nm in mean diameter, about 1 nm to about 100 nm in mean diameter, about 1 nm to about 90 nm in mean diameter, about 1 nm to about 80 nm in mean diameter, about 1 nm to about 70 nm in mean diameter, about 1 nm to about 60 nm in mean diameter, about 1 nm to about 50 nm in mean diameter, about 1 nm to about 40 nm in mean diameter, about 1 nm to about 30 nm in mean diameter, or about 1 nm to about 20 nm in mean diameter, about 1 nm to about 10 nm in mean diameter. In other aspects, the size of the nanoparticles is from about 5 nm to about 150 nm (mean diameter), from about 5 to about 50 nm, from about 10 to about 30 nm. The size of the nanoparticles is from about 5 nm to about 150 nm (mean diameter), from about 30 to about 100 nm, from about 40 to about 80 nm. The size of the nanoparticles used in a method varies as required by their particular use or application. The variation of size is advantageously used to optimize certain physical characteristics of the nanoparticles, for example, optical properties or amount surface area that can be derivatized as described herein.

#### NANOPARTICLE TARGETING AGENTS

25 **[0052]** In certain embodiments of the methods, the nanoparticle is optionally labeled and in various aspects of these embodiment, the nanoparticle comprises one or more targeting moieties, including but not limited to proteins, including antibodies, peptides, small molecules, anticancer agents, polynucleotide-binding agents, carbohydrates, lipids, ligands for cell surface receptors, and the like. Targeting moieties are useful for delivery of the functionalized nanoparticle to specific cell types and/or organs, as well as sub-cellular locations.

30 **[0053]** Accordingly, targeting agent contemplated include nuclear localization signals (NLS) and peptide transduction domains, including, for example, SV40 large T NLS, HIV-1 TAT protein NLS, adenovirus NLS, integrin binding domain, oligolysine (each of which is described in (Tkachenko, et al., *Bioconjugate Chem* (2004) 15:482-490), and adenovirus fiber protein comprising both NLS and receptor-mediated endocytosis (RME) domains (Tkachenko, et al., *Am. Chem. Soc.* (2003) 125:4700-4701).

#### OLIGONUCLEOTIDE FEATURES

35 **[0054]** Oligonucleotides contemplated for attachment to a nanoparticle include those which modulate expression of a gene product expressed from a target polynucleotide. Accordingly, antisense oligonucleotides which hybridize to a target polynucleotide and inhibit translation, siRNA oligonucleotides which hybridize to a target polynucleotide and initiate an RNase activity (for example RNase H), triple helix forming oligonucleotides which hybridize to double-stranded polynucleotides and inhibit transcription, and ribozymes which hybridize to a target polynucleotide and inhibit translation, are contemplated.

40 **[0055]** Each nanoparticle utilized in the methods provided has a plurality of oligonucleotides attached to it. As a result, each nanoparticle-oligonucleotide conjugate has the ability to bind to a plurality of target polynucleotides having a sufficiently complementary sequence. For example, if a specific mRNA is targeted, a single nanoparticle has the ability to bind to multiple copies of the same transcript. In one aspect, methods are provided wherein the nanoparticle is functionalized with identical oligonucleotides, *i.e.*, each oligonucleotide has the same length and the same sequence. In other aspects, the nanoparticle is functionalized with two or more oligonucleotides which are not identical, *i.e.*, at least one of the attached oligonucleotides differ from at least one other attached oligonucleotide in that it has a different length and/or a different sequence. In aspects wherein different oligonucleotides are attached to the nanoparticle, these different oligonucleotides bind to the same single target polynucleotide but at different locations, or bind to different target polynucleotides which encode different gene products. Accordingly, in various aspects, a single functionalized nanoparticle may be used a method to inhibit expression of more than one gene product. Oligonucleotides are thus used to target specific polynucleotides, whether at one or more specific regions in the target polynucleotide, or over the entire length of the target polynucleotide as the need may be to effect a desired level of inhibition of gene expression.

55 **[0056]** Accordingly, the oligonucleotides are designed with knowledge of the target sequence. Methods of making oligonucleotides of a predetermined sequence are well-known. See, for example, Sambrook et al., *Molecular Cloning*:



A Laboratory Manual (2nd ed. 1989) and F. Eckstein (ed.) Oligonucleotides and Analogues, 1st Ed. (Oxford University Press, New York, 1991). Solid-phase synthesis methods are contemplated for both oligoribonucleotides and oligodeoxyribonucleotides (the well-known methods of synthesizing DNA are also useful for synthesizing RNA). Oligoribonucleotides and oligodeoxyribonucleotides can also be prepared enzymatically.

**[0057]** Alternatively, oligonucleotides are selected from a library. Preparation of libraries of this type is well known in the art. See, for example, Oligonucleotide libraries: United States Patent Application 20050214782, published September 29, 2005.

**[0058]** In another aspect, methods are provided wherein the oligonucleotide is functionalized to the nanoparticle in such a way that the oligonucleotide is released from the nanoparticle after the nanoparticle enters a cell. In general an oligonucleotide can be released from the surface of a nanoparticle using either chemical methods, photon release (i.e., irradiating cells in which nanoparticles have entered using an electromagnetic wavelength chosen based on the nanoparticle size), and changes in ionic or acid/base environment.

**[0059]** In one aspect of this embodiment, the oligonucleotide is attached to the nanoparticle via an acid-labile moiety and once the functionalized nanoparticle is taken into the cell via, for example, an endosome, acidification of the endosome (a normal part of endosomal uptake) releases the oligonucleotides. This aspect is particularly useful in instances where the intent is to saturate the cell with for example, an siRNA and release from the nanoparticle would improve kinetics and resolve potential steric hindrance problems. RNAi for modulating gene expression is well known in the art and generally described in, for example, United States Patent Application 20060019917, United States Patent Application 20060008907 and United States Patent Application 20050059016, the disclosures of which are incorporated herein by reference in their entireties. Preparation of siRNA oligonucleotide libraries is generally described in United States Patent Application 20050197315.

#### OLIGONUCLEOTIDE LENGTH

**[0060]** The term "oligonucleotides" as used herein includes modified forms as discussed herein as well as those otherwise known in the art which are used to regulate gene expression. Likewise, the term "nucleotides" as used herein is interchangeable with modified forms as discussed herein and otherwise known in the art. In certain instances, the art uses the term "nucleobase" which embraces naturally-occurring nucleotides as well as modifications of nucleotides that can be polymerized into a molecule that functions as antisense. Herein, the terms "nucleotides" and "nucleobases" are used interchangeably to embrace the same scope unless otherwise noted.

**[0061]** Nanoparticles for use in the methods provided are functionalized with an oligonucleotide, or modified form thereof, which is from about 5 to about 100 nucleotides in length. Methods are also contemplated wherein the oligonucleotide is about 5 to about 90 nucleotides in length, about 5 to about 80 nucleotides in length, about 5 to about 70 nucleotides in length, about 5 to about 60 nucleotides in length, about 5 to about 50 nucleotides in length about 5 to about 45 nucleotides in length, about 5 to about 40 nucleotides in length, about 5 to about 35 nucleotides in length, about 5 to about 30 nucleotides in length, about 5 to about 25 nucleotides in length, about 5 to about 20 nucleotides in length, about 5 to about 15 nucleotides in length, about 5 to about 10 nucleotides in length, and all oligonucleotides intermediate in length of the sizes specifically disclosed to the extent that the oligonucleotide is able to achieve the desired result. Accordingly, oligonucleotides of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100 nucleotides in length are contemplated.

**[0062]** In still other aspects, oligonucleotides comprise from about 8 to about 80 nucleotides (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that methods utilize compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotide in length.

#### OLIGONUCLEOTIDE COMPLEMENTARITY

**[0063]** "Hybridization" means an interaction between two strands of nucleic acids by hydrogen bonds in accordance with the rules of Watson-Crick DNA complementarity, Hoogsteen binding, or other sequence-specific binding known in the art. Hybridization can be performed under different stringency conditions known in the art. Under appropriate stringency conditions, hybridization between the two complementary strands could reach about 60% or above, about 70% or above, about 80% or above, about 90% or above, about 95% or above, about 96% or above, about 97% or above, about 98% or above, or about 99% or above in the reactions. It will be understood by those of skill in the art that the degree of hybridization is less significant than a resulting degree of inhibition of gene product expression.

**[0064]** In various aspects, the methods include use of an oligonucleotide which is 100% complementary to the target

polynucleotide, *i.e.*, a perfect match, while in other aspects, the oligonucleotide is at least (meaning greater than or equal to) about 95% complementary to the polynucleotide over the length of the oligonucleotide, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about 55%, at least about 50%, at least about 45%, at least about 40%, at least about 35%, at least about 30%, at least about 25%, at least about 20% complementary to the polynucleotide over the length of the oligonucleotide to the extent that the oligonucleotide is able to achieve the desired degree of inhibition of a target gene product.

**[0065]** It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). The percent complementarity is determined over the length of the oligonucleotide. For example, given an antisense compound in which 18 of 20 nucleotides of the antisense compound are complementary to a 20 nucleotide region in a target polynucleotide of 100 nucleotides total length, the oligonucleotide would be 90 percent complementary. In this example, the remaining noncomplementary nucleotides may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleotides. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403-410; Zhang and Madden, *Genome Res.*, 1997, 7, 649-656).

**[0066]** In various aspect, the oligonucleotide has a sequence that introduces or induces changes in secondary structure of the target polynucleotide, including but not limited to one or more loops or hairpin structures.

#### OLIGONUCLEOTIDE ATTACHMENT

**[0067]** Oligonucleotides contemplated for use in the methods include those bound to the nanoparticle through any means. Regardless of the means by which the oligonucleotide is attached to the nanoparticle, attachment in various aspects is effected through a 5' linkage, a 3' linkage, some type of internal linkage, or any combination of these attachments.

**[0068]** In one aspect, the nanoparticles, the oligonucleotides or both are functionalized in order to attach the oligonucleotides to the nanoparticles. Methods to functionalize nanoparticles and oligonucleotides are known in the art. For instance, oligonucleotides functionalized with alkanethiols at their 3'-termini or 5'-termini readily attach to gold nanoparticles. See Whitesides, *Proceedings of the Robert A. Welch Foundation 39th Conference On Chemical Research Nanophase Chemistry*, Houston, Tex., pages 109-121 (1995). See also, Mucic et al. *Chem. Commun.* 555-557 (1996) which describes a method of attaching 3' thiol DNA to flat gold surfaces. The alkanethiol method can also be used to attach oligonucleotides to other metal, semiconductor and magnetic colloids and to the other types of nanoparticles described herein. Other functional groups for attaching oligonucleotides to solid surfaces include phosphorothioate groups (see, for example, U.S. Pat. No. 5,472,881 for the binding of oligonucleotide-phosphorothioates to gold surfaces), substituted alkylsiloxanes (see, for example, Burwell, *Chemical Technology*, 4, 370-377 (1974) and Matteucci and Caruthers, *J. Am. Chem. Soc.*, 103, 3185-3191 (1981) for binding of oligonucleotides to silica and glass surfaces, and Grabar et al., *Anal. Chem.*, 67, 735-743 for binding of aminoalkylsiloxanes and for similar binding of mercaptoalkylsiloxanes). Oligonucleotides with a 5' thionucleoside or a 3' thionucleoside may also be used for attaching oligonucleotides to solid surfaces. The following references describe other methods which may be employed to attached oligonucleotides to nanoparticles: Nuzzo et al., *J. Am. Chem. Soc.*, 109, 2358 (1987) (disulfides on gold); Allara and Nuzzo, *Langmuir*, 1, 45 (1985) (carboxylic acids on aluminum); Allara and Tompkins, *J. Colloid Interface Sci.*, 49, 410-421 (1974) (carboxylic acids on copper); Iler, *The Chemistry Of Silica*, Chapter 6, (Wiley 1979) (carboxylic acids on silica); Timmons and Zisman, *J. Phys. Chem.*, 69, 984-990 (1965) (carboxylic acids on platinum); Soriaga and Hubbard, *J. Am. Chem. Soc.*, 104, 3937 (1982) (aromatic ring compounds on platinum); Hubbard, *Acc. Chem. Res.*, 13, 177 (1980) (sulfolanes, sulfoxides and other functionalized solvents on platinum); Hickman et al., *J. Am. Chem. Soc.*, 111, 7271 (1989) (isonitriles on platinum); Maoz and Sagiv, *Langmuir*, 3, 1045 (1987) (silanes on silica); Maoz and Sagiv, *Langmuir*, 3, 1034 (1987) (silanes on silica); Wasserman et al., *Langmuir*, 5, 1074 (1989) (silanes on silica); Eltekova and Eltekov, *Langmuir*, 3, 951 (1987) (aromatic carboxylic acids, aldehydes, alcohols and methoxy groups on titanium dioxide and silica); Lec et al., *J. Phys. Chem.*, 92, 2597 (1988) (rigid phosphates on metals).

**[0069]** U.S. patent application Ser. Nos. 09/760,500 and 09/820,279 and international application nos. PCT/US01/01190 and PCT/US01/10071 describe oligonucleotides functionalized with a cyclic disulfide. The cyclic disulfides in certain aspects have 5 or 6 atoms in their rings, including the two sulfur atoms. Suitable cyclic disulfides are available commercially or are synthesized by known procedures. Functionalization with the reduced forms of the cyclic disulfides is also contemplated.

**[0070]** In certain aspects wherein cyclic disulfide functionalization, oligonucleotides are attached to a nanoparticle through one or more linkers. In one embodiment, the linker comprises a hydrocarbon moiety attached to a cyclic disulfide. Suitable hydrocarbons are available commercially, and are attached to the cyclic disulfides. The hydrocarbon moiety is,

in one aspect, a steroid residue. Oligonucleotide-nanoparticle conjugates prepared using linkers comprising a steroid residue attached to a cyclic disulfide are more stable to thiols compared to conjugates prepared using alkanethiols or acyclic disulfides as the linker, and in certain instances, the oligonucleotide-nanoparticle conjugates have been found to be 300 times more stable. In certain embodiments, the two sulfur atoms of the cyclic disulfide are close enough together so that both of the sulfur atoms attach simultaneously to the nanoparticle. In other aspects, the two sulfur atoms are adjacent each other. In aspects where utilized, the hydrocarbon moiety is large enough to present a hydrophobic surface screening the surfaces of the nanoparticle.

**[0071]** In other aspects, a method for attaching oligonucleotides onto a surface is based on an aging process described in U.S. application Ser. No. 09/344,667, filed Jun. 25, 1999; Ser. No. 09/603,830, filed Jun. 26, 2000; Ser. No. 09/760,500, filed Jan. 12, 2001; Ser. No. 09/820,279, filed Mar. 28, 2001; Ser. No. 09/927,777, filed Aug. 10, 2001; and in International application nos. PCT/US97/12783, filed Jul. 21, 1997; PCT/US00/17507, filed Jun. 26, 2000; PCT/US01/01190, filed Jan. 12, 2001; PCT/US01/10071, filed Mar. 28, 2001. The aging process provides nanoparticle-oligonucleotide conjugates with enhanced stability and selectivity. The process comprises providing oligonucleotides, in one aspect, having covalently bound thereto a moiety comprising a functional group which can bind to the nanoparticles. The moieties and functional groups are those that allow for binding (i.e., by chemisorption or covalent bonding) of the oligonucleotides to nanoparticles. For example, oligonucleotides having an alkanethiol, an alkanedisulfide or a cyclic disulfide covalently bound to their 5' or 3' ends bind the oligonucleotides to a variety of nanoparticles, including gold nanoparticles.

**[0072]** Conjugates produced by use of the "aging" step have been found to be considerably more stable than those produced without the "aging" step. Increased density of the oligonucleotides on the surfaces of the nanoparticles is achieved by the "aging" step. The surface density achieved by the "aging" step will depend on the size and type of nanoparticles and on the length, sequence and concentration of the oligonucleotides. A surface density adequate to make the nanoparticles stable and the conditions necessary to obtain it for a desired combination of nanoparticles and oligonucleotides can be determined empirically. Generally, a surface density of at least 10 picomoles/cm<sup>2</sup> will be adequate to provide stable nanoparticle-oligonucleotide conjugates. In certain aspects, the surface density is at least 15 picomoles/cm<sup>2</sup>. Since the ability of the oligonucleotides of the conjugates to hybridize with nucleic acid and oligonucleotide targets can be diminished if the surface density is too great, the surface density is, in one aspect, no greater than about 35-40 picomoles/cm<sup>2</sup>. Regardless, various oligonucleotide densities are contemplated as disclosed herein.

**[0073]** An "aging" step is incorporated into production of functionalized nanoparticles following an initial binding or oligonucleotides to a nanoparticle. In brief, the oligonucleotides are contacted with the nanoparticles in water for a time sufficient to allow at least some of the oligonucleotides to bind to the nanoparticles by means of the functional groups. Such times can be determined empirically. In one aspect, a time of about 12-24 hours is contemplated. Other suitable conditions for binding of the oligonucleotides can also be determined empirically. For example, a concentration of about 10-20 nM nanoparticles and incubation at room temperature is contemplated.

**[0074]** Next, at least one salt is added to the water to form a salt solution. The salt is any water-soluble salt, including, for example and without limitation, sodium chloride, magnesium chloride, potassium chloride, ammonium chloride, sodium acetate, ammonium acetate; a combination of two or more of these salts, or one of these salts in phosphate buffer. The salt is added as a concentrated solution, or in the alternative as a solid. In various embodiments, the salt is added all at one time or the salt is added gradually over time. By "gradually over time" is meant that the salt is added in at least two portions at intervals spaced apart by a period of time. Suitable time intervals can be determined empirically.

**[0075]** The ionic strength of the salt solution must be sufficient to overcome at least partially the electrostatic repulsion of the oligonucleotides from each other and, either the electrostatic attraction of the negatively-charged oligonucleotides for positively-charged nanoparticles, or the electrostatic repulsion of the negatively-charged oligonucleotides from negatively-charged nanoparticles. Gradually reducing the electrostatic attraction and repulsion by adding the salt gradually over time gives the highest surface density of oligonucleotides on the nanoparticles. Suitable ionic strengths can be determined empirically for each salt or combination of salts. In one aspect, a final concentration of sodium chloride of from about 0.1 M to about 1.0 M in phosphate buffer is utilized, with the concentration of sodium chloride being increased gradually over time.

**[0076]** After adding the salt, the oligonucleotides and nanoparticles are incubated in the salt solution for a period of time to allow additional oligonucleotides to bind to the nanoparticles to produce the stable nanoparticle-oligonucleotide conjugates. As will be described in detail below, an increased surface density of the oligonucleotides on the nanoparticles stabilizes the conjugates. The time of this incubation can be determined empirically. By way of example, in one aspect a total incubation time of about 24-48, wherein the salt concentration is increased gradually over this total time, is contemplated. This second period of incubation in the salt solution is referred to herein as the "aging" step. Other suitable conditions for this "aging" step can also be determined empirically. By way of example, an aging step is carried out with incubation at room temperature and pH 7.0.

**[0077]** The conjugates produced by use of the "aging" are in general more stable than those produced without the "aging" step. As noted above, this increased stability is due to the increased density of the oligonucleotides on the surfaces of the nanoparticles which is achieved by the "aging" step. The surface density achieved by the "aging" step

will depend on the size and type of nanoparticles and on the length, sequence and concentration of the oligonucleotides.

**[0078]** As used herein, "stable" means that, for a period of at least six months after the conjugates are made, a majority of the oligonucleotides remain attached to the nanoparticles and the oligonucleotides are able to hybridize with nucleic acid and oligonucleotide targets under standard conditions encountered in methods of detecting nucleic acid and methods of nanofabrication.

#### OLIGONUCLEOTIDE DENSITY

**[0079]** Methods are provided wherein the oligonucleotide is bound to the nanoparticle at a surface density of at least about 0.3 pmol/cm<sup>2</sup>, at least about 0.6 pmol/cm<sup>2</sup>, at least about 0.9 pmol/cm<sup>2</sup>, at least about 1.2 pmol/cm<sup>2</sup>, at least about 1.5 pmol/cm<sup>2</sup>, at least about 1.8 pmol/cm<sup>2</sup>, at least about 2.1 pmol/cm<sup>2</sup>, at least about 2.4 pmol/cm<sup>2</sup>, at least about 2.7 pmol/cm<sup>2</sup>, at least about 3.0 pmol/cm<sup>2</sup>, at least about 3.3 pmol/cm<sup>2</sup>, at least about 3.6 pmol/cm<sup>2</sup>, at least about 3.9 pmol/cm<sup>2</sup>, at least about 4.2 pmol/cm<sup>2</sup>, at least about 4.5 pmol/cm<sup>2</sup>, at least about 4.8 pmol/cm<sup>2</sup>, at least about 5.1 pmol/cm<sup>2</sup>, at least about 5.4 pmol/cm<sup>2</sup>, at least about 5.7 pmol/cm<sup>2</sup>, at least about 6.0 pmol/cm<sup>2</sup>, at least about 6.3 pmol/cm<sup>2</sup>, at least about 6.6 pmol/cm<sup>2</sup>, at least about 6.9 pmol/cm<sup>2</sup>, at least about 7.2 pmol/cm<sup>2</sup>, at least about 7.5 pmol/cm<sup>2</sup>, at least about 7.8 pmol/cm<sup>2</sup>, at least about 8.1 pmol/cm<sup>2</sup>, at least about 8.4 pmol/cm<sup>2</sup>, at least about 8.7 pmol/cm<sup>2</sup>, at least about 9.0 pmol/cm<sup>2</sup>, at least about 9.3 pmol/cm<sup>2</sup>, at least about 9.6 pmol/cm<sup>2</sup>, at least about 9.9 pmol/cm<sup>2</sup>, at least 10 pmol/cm<sup>2</sup>, at least 15 pmol/cm<sup>2</sup>, at least 20 pmol/cm<sup>2</sup>, at least 25 pmol/cm<sup>2</sup>, at least 30 pmol/cm<sup>2</sup>, at least 35 pmol/cm<sup>2</sup>, at least 40 pmol/cm<sup>2</sup>, at least 45 pmol/cm<sup>2</sup>, at least 50 pmol/cm<sup>2</sup>, or 50 pmol/cm<sup>2</sup> or more.

**[0080]** In one aspect, methods are provided wherein the packing density of the oligonucleotides on the surface of the nanoparticle is sufficient to result in cooperative behavior between nanoparticles. Methods include those wherein cooperative behavior between the nanoparticles increases the strength of the binding between the oligonucleotide and the target polynucleotide.

**[0081]** In another aspect, the cooperative behavior between the nanoparticles increases the resistance of the oligonucleotide to degradation, and/or increases the resistance of the oligonucleotide/polynucleotide complex to degradation. In certain aspects, cooperative behavior between the nanoparticles increases in the resistance of the oligonucleotides to degradation by a nuclease.

**[0082]** Methods also include those wherein the uptake of a nanoparticle of the invention can be modulated as a function of packing density of oligonucleotides on said nanoparticle. As shown herein, increasing oligonucleotide packing density on a first nanoparticle increases uptake of the nanoparticle compared to uptake of a second nanoparticle at a lower oligonucleotide packing density. Thus, in various aspects, the modulation of uptake may be either an increase or decrease in uptake. In still other aspects, the uptake of a first nanoparticle may be modulated at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, at least 5-fold, at least 5.5-fold, at least 6-fold, at least 6.5-fold, at least 7-fold, at least 7.5-fold, at least 8-fold, at least 8.5-fold, at least 9-fold, at least 9.5-fold, at least 10-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, or at least 100-fold or more compared to the uptake of a second nanoparticle having a packing density different from the first nanoparticle.

**[0083]** In one aspect, methods are contemplated in which one oligonucleotide is functionalized on a nanoparticle. In other aspects, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 oligonucleotides are functionalized on a nanoparticle. In still other aspects, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, at least 85, at least 90, at least 95, at least 100 or more oligonucleotides are functionalized on a nanoparticle.

**[0084]** In one aspect, methods are contemplated wherein the packing density of the oligonucleotides on a first nanoparticle is increased by at least 1% compared to the packing density on a second nanoparticle. In other aspects, the packing density of the oligonucleotides on a first nanoparticle is increased by at least 2% compared to the packing density on a second nanoparticle. In still other aspects, the packing density of the oligonucleotides on a first nanoparticle is increased by at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, at least 5-fold, at least 5.5-fold, at least 6-fold, at least 6.5-fold, at least 7-fold, at least 7.5-fold, at least 8-fold, at least 8.5-fold, at least 9-fold, at least 9.5-fold, at least 10-fold,

at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, or at least 100-fold or more compared to the packing density on a second nanoparticle.

**[0085]** In some aspects, increasing the packing density of oligonucleotides on a nanoparticle results in increasing numbers of proteins adsorbed to the oligonucleotide-functionalized nanoparticle. The proteins may originate from a number of sources, including but not limited to serum in cell culture medium, the extracellular matrix, cell-associated proteins, engineered proteins, cell-bound proteins, and circulating proteins. Without being bound by any theory or mechanism, the proteins may interact with the oligonucleotide-functionalized nanoparticle, and a higher number of oligonucleotides per nanoparticle results in a higher number of proteins adsorbed onto the oligonucleotide-functionalized nanoparticle, which in turn may allow for increased uptake of the nanoparticle compared to a nanoparticle having a lower number of oligonucleotides functionalized thereon.

**[0086]** In additional aspects, modulating the packing density of oligonucleotides on a nanoparticle is effected through the use of diluents. OEG is one such diluent that is useful due to its charge neutrality, water solubility, and its ability to passivate surfaces in a manner that resists adsorption of biological molecules (Prime et al., 1991 Science 252(5009): 1164-1167). In various aspects, diluent molecules are included in order to keep the Au NP surface fully passivated and the particles stable. In some aspects, the OEG diluent allows ASNPs to be synthesized with zero to  $80 \pm 2$  oligonucleotides per particle that are stable under all the conditions required for cell culture.

#### OLIGONUCLEOTIDE COPIES - SAME/DIFFERENT SEQUENCES

**[0087]** The term "oligonucleotide" includes those wherein a single sequence is attached to a nanoparticle, or multiple copies of the single sequence are attached. For example, in various aspects, an oligonucleotide is present in multiple copies in tandem, for example, two, three, four, five, six, seven eight, nine, ten or more tandem repeats.

**[0088]** Alternatively, the nanoparticle is functionalized to include at least two oligonucleotides having different sequences. As above, the different oligonucleotide sequences are in various aspects arranged in tandem and/or in multiple copies. Alternatively, the oligonucleotides having different sequences are attached directly to the nanoparticle. In methods wherein oligonucleotides having different sequences are attached to the nanoparticle, aspects of the methods include those wherein the different oligonucleotide sequences hybridize to different regions on the same polynucleotide. Alternatively, the different oligonucleotide sequences hybridize to different polynucleotides, thereby modulating gene expression from different target polynucleotides.

**[0089]** The oligonucleotides on the nanoparticles may all have the same sequence or may have different sequences that hybridize with different portions of the target polynucleotide. When oligonucleotides having different sequences are used, each nanoparticle may have all of the different oligonucleotides attached to it or the different oligonucleotides are attached to different nanoparticles. Alternatively, the oligonucleotides on each of the nanoparticles may have a plurality of different sequences, at least one of which must hybridize with a portion of the target polynucleotide.

**[0090]** In another aspect, multiple oligonucleotide are bound on a particle which allow for the ability to crosslink target polynucleotide via either inter- or intra-strand links. Crosslinking in this manner potentiates inhibition by various means including steric hindrance.

#### SPACERS

**[0091]** In certain aspect, functionalized nanoparticles are contemplated which include those wherein an oligonucleotide is attached to the nanoparticle through a spacer. "Spacer" as used herein means a moiety that does not participate in modulating gene expression *per se* but which serves to increase distance between the nanoparticle and the functional oligonucleotide, or to increase distance between individual oligonucleotides when attached to the nanoparticle in multiple copies. Thus, spacers are contemplated being located between individual oligonucleotide in tandem, whether the oligonucleotides have the same sequence or have different sequences. In one aspect, the spacer when present is an organic moiety. In another aspect, the spacer is a polymer, including but not limited to a water-soluble polymer, a nucleic acid, a polypeptide, an oligosaccharide, a carbohydrate, a lipid, an ethylglycol, or combinations thereof.

**[0092]** In certain aspects, the spacer has a moiety covalently bound to it, the moiety comprising a functional group which can bind to the nanoparticles. These are the same moieties and functional groups as described above. As a result of the binding of the spacer to the nanoparticles, the oligonucleotide is spaced away from the surface of the nanoparticles and is more accessible for hybridization with its target. In instances wherein the spacer is a polynucleotide, the length of the spacer in various embodiments at least about 10 nucleotides, 10-30 nucleotides, or even greater than 30 nucleotides. The spacer may have any sequence which does not interfere with the ability of the oligonucleotides to become bound to the nanoparticles or to the target polynucleotide. The spacers should not have sequences complementary to each other or to that of the oligonucleotides, but may be all or in part complementary to the target polynucleotide. In certain aspects, the bases of the polynucleotide spacer are all adenines, all thymines, all cytidines, all guanines, all uracils, or all some other modified base.

**[0093]** In another embodiment, a non-nucleotide linker of the invention comprises a basic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds. Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma et al., *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand et al., *Nucleic Acids Res.* 1990, 18:6353; McCurdy et al., *Nucleosides & Nucleotides* 1991, 10:287; Jsckke et al., *Tetrahedron Lett.* 1993, 34:301; Ono et al., *Biochemistry* 1991, 30:9914; Arnold et al., International Publication No. WO 89/02439; Usman et al., International Publication No. WO 95/06731; Dudycz et al., International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000. A "non-nucleotide" further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.

**[0094]** In various aspects, linkers contemplated include linear polymers (e.g., polyethylene glycol, polylysine, dextran, etc.), branched-chain polymers (see, for example, U.S. Patent 4,289,872 to Denkenwalter et al., issued September 15, 1981; 5,229,490 to Tam, issued July 20, 1993; WO 93/21259 by Frechet et al., published 28 October 1993); lipids; cholesterol groups (such as a steroid); or carbohydrates or oligosaccharides. Other linkers include one or more water soluble polymer attachments such as polyoxyethylene glycol, or polypropylene glycol as described U.S. Patent Nos: 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 and 4,179,337. Other useful polymers as linkers known in the art include monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures of these polymers.

**[0095]** In still other aspects, oligonucleotide such as poly-A or hydrophilic or amphiphilic polymers are contemplated as linkers, including, for example, amphiphiles (including oligonucleotides).

#### TYPES OF OLIGONUCLEOTIDES, INCLUDING MODIFIED FORMS

**[0096]** In various aspects, methods include oligonucleotides which are DNA oligonucleotides, RNA oligonucleotides, or combinations of the two types. Modified forms of oligonucleotides are also contemplated which include those having at least one modified internucleotide linkage. In one embodiment, the oligonucleotide is all or in part a peptide nucleic acid. Other modified internucleoside linkages include at least one phosphorothioate linkage. Still other modified oligonucleotides include those comprising one or more universal bases. "Universal base" refers to molecules capable of substituting for binding to any one of A, C, G, T and U in nucleic acids by forming hydrogen bonds without significant structure destabilization. The oligonucleotide incorporated with the universal base analogues is able to function as a probe in hybridization, as a primer in PCR and DNA sequencing. Examples of universal bases include but are not limited to 5'-nitroindole-2'-deoxyriboside, 3-nitropyrrole, inosine and pypoxanthine.

#### Modified Internucleoside Linkages

**[0097]** Specific examples of oligonucleotides include those containing modified backbones or non-natural internucleoside linkages. Oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone are considered to be within the meaning of "oligonucleotide".

**[0098]** Modified oligonucleotide backbones containing a phosphorus atom include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Also contemplated are oligonucleotides having inverted polarity comprising a single 3' to 3' linkage at the 3'-most internucleotide linkage, i.e. a single inverted nucleoside residue which may be abasic (the nucleotide is missing or has a hydroxyl group in place thereof). Salts, mixed salts and free acid forms are also contemplated. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, the disclosures of which are incorporated by reference herein.

**[0099]** Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are

formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages; siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. See, for example, U.S. Patent Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, the disclosures of which are incorporated herein by reference in their entireties.

#### Modified sugar and internucleoside linkages

**[0100]** In still other embodiments, oligonucleotide mimetics wherein both one or more sugar and/or one or more internucleotide linkage of the nucleotide units are replaced with "non-naturally occurring" groups. The bases of the oligonucleotide are maintained for hybridization with the target polynucleotide. In one aspect, this embodiment contemplates a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone. See, for example US Patent Nos. 5,539,082; 5,714,331; and 5,719,262, and Nielsen et al., Science, 1991, 254, 1497-1500, the disclosures of which are herein incorporated by reference.

**[0101]** In still other embodiments, oligonucleotides are provided with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and including -CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>-, -CH<sub>2</sub>-O-N(CH<sub>3</sub>)-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-N(CH<sub>3</sub>)-CH<sub>2</sub>- and -O-N(CH<sub>3</sub>)-CH<sub>2</sub>-CH<sub>2</sub>- described in US Patent Nos. 5,489,677, and 5,602,240. Also contemplated are oligonucleotides with morpholino backbone structures described in US Patent No. 5,034,506.

**[0102]** In various forms, the linkage between two successive monomers in the oligo consists of 2 to 4, desirably 3, groups/atoms selected from -CH<sub>2</sub>-, -O-, -S-, -NR<sup>H</sup>-, >C=O, >C=NR<sup>H</sup>, >C=S, -Si(R<sup>"</sup>)<sub>2</sub>-, -SO-, -S(O)<sub>2</sub>-, -P(O)<sub>2</sub>-, -PO(BH<sub>3</sub>)-, -P(O,S)-, -P(S)<sub>2</sub>-, -PO(R<sup>"</sup>)-, -PO(OCH<sub>3</sub>)-, and -PO(NHR<sup>H</sup>)-, where RH is selected from hydrogen and C<sub>1-4</sub>-alkyl, and R<sup>"</sup> is selected from C<sub>1-6</sub>-alkyl and phenyl. Illustrative examples of such linkages are -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CO-CH<sub>2</sub>-, -CH<sub>2</sub>-CHOH-CH<sub>2</sub>-, -O-CH<sub>2</sub>-O-, -O-CH<sub>2</sub>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH=(including R<sup>5</sup> when used as a linkage to a succeeding monomer), -CH<sub>2</sub>-CH<sub>2</sub>-O-, -NR<sup>H</sup>-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-NR<sup>H</sup>-, -CH<sub>2</sub>-NR<sup>H</sup>-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-NR<sup>H</sup>-, -NR<sup>H</sup>-CO-O-, -NR<sup>H</sup>-CO-NR<sup>H</sup>-, -NR<sup>H</sup>-CS-NR<sup>H</sup>-, -NR<sup>H</sup>-C(=NR<sup>H</sup>)-NR<sup>H</sup>-, -NR<sup>H</sup>-CO-CH<sub>2</sub>-NR<sup>H</sup>-O-CO-O-, -O-CO-CH<sub>2</sub>-O-, -O-CH<sub>2</sub>-CO-O-, -CH<sub>2</sub>-CO-NR<sup>H</sup>-, -O-CO-NR<sup>H</sup>-, -NR<sup>H</sup>-CO-CH<sub>2</sub>-, -O-CH<sub>2</sub>-CO-NR<sup>H</sup>-, -O-CH<sub>2</sub>-CH<sub>2</sub>-NR<sup>H</sup>-, -CH=N-O-, -CH<sub>2</sub>-NR<sup>H</sup>-O-, -CH<sub>2</sub>-O-N=(including R<sup>5</sup> when used as a linkage to a succeeding monomer), -CH<sub>2</sub>-O-NR<sup>H</sup>-, -CO-NR<sup>H</sup>-CH<sub>2</sub>-, -CH<sub>2</sub>-NR<sup>H</sup>-O-, -CH<sub>2</sub>-NR<sup>H</sup>-CO-, -O-NR<sup>H</sup>-CH<sub>2</sub>-, -O-NR<sup>H</sup>-, -O-CH<sub>2</sub>-S-, -S-CH<sub>2</sub>-O-, -CH<sub>2</sub>-CH<sub>2</sub>-S-, -O-CH<sub>2</sub>-CH<sub>2</sub>-S-, -S-CH<sub>2</sub>-CH=(including R<sup>5</sup> when used as a linkage to a succeeding monomer), -S-CH<sub>2</sub>-CH<sub>2</sub>-, -S-CH<sub>2</sub>-CH<sub>2</sub>-O-, -S-CH<sub>2</sub>-CH<sub>2</sub>-S-, -CH<sub>2</sub>-S-CH<sub>2</sub>-, -CH<sub>2</sub>-SO-CH<sub>2</sub>-, -CH<sub>2</sub>-SO<sub>2</sub>-CH<sub>2</sub>-, -O-SO-O-, -O-S(O)<sub>2</sub>-O-, -O-S(O)<sub>2</sub>-CH<sub>2</sub>-, -O-S(O)<sub>2</sub>-NR<sup>H</sup>-, -NR<sup>H</sup>-S(O)<sub>2</sub>-CH<sub>2</sub>-, -O-S(O)<sub>2</sub>-CH<sub>2</sub>-, -O-P(O)<sub>2</sub>-O-, -O-P(O,S)-O-, -O-P(S)<sub>2</sub>-O-, -S-P(O)<sub>2</sub>-O-, -S-P(O,S)-O-, -S-P(S)<sub>2</sub>-O-, -O-P(O)<sub>2</sub>-S-, -O-P(O,S)-S-, -O-P(S)<sub>2</sub>-S-, -S-P(O)<sub>2</sub>-S-, -S-P(O,S)-S-, -S-P(S)<sub>2</sub>-S-, -O-PO(R<sup>"</sup>)-O-, -O-PO(OCH<sub>3</sub>)-O-, -O-PO(OCH<sub>2</sub>CH<sub>3</sub>)-O-, -O-PO(OCH<sub>2</sub>CH<sub>2</sub>S-R)-O-, -O-PO(BH<sub>3</sub>)-O-, -O-PO(NHR<sup>N</sup>)-O-, -O-P(O)<sub>2</sub>-NR<sup>H</sup>-, -NR<sup>H</sup>-P(O)<sub>2</sub>-O-, -O-P(O,NR<sup>H</sup>)-O-, -CH<sub>2</sub>-P(O)<sub>2</sub>-O-, -O-P(O)<sub>2</sub>-CH<sub>2</sub>-, and -O-Si(R<sup>"</sup>)<sub>2</sub>-O-; among which -CH<sub>2</sub>-CO-NR<sup>H</sup>-, -CH<sub>2</sub>-NR<sup>H</sup>-O-, -S-CH<sub>2</sub>-O-, -O-P(O)<sub>2</sub>-O-O-P(O,S)-O-, -O-P(S)<sub>2</sub>-O-, -NR<sup>H</sup>P(O)<sub>2</sub>-O-, -O-P(O,NR<sup>H</sup>)-O-, -O-PO(R<sup>"</sup>)-O-, -O-PO(CH<sub>3</sub>)-O-, and -O-PO(NHR<sup>N</sup>)-O-, where RH is selected from hydrogen and C<sub>1-4</sub>-alkyl, and R<sup>"</sup> is selected from C<sub>1-6</sub>-alkyl and phenyl, are contemplated. Further illustrative examples are given in Mesmaeker et. al., Current Opinion in Structural Biology 1995, 5, 343-355 and Susan M. Freier and Karl-Heinz Altmann, Nucleic Acids Research, 1997, vol 25, pp 4429-4443.

**[0103]** Still other modified forms of oligonucleotides are described in detail in U.S. patent application NO. 20040219565.

**[0104]** Modified oligonucleotides may also contain one or more substituted sugar moieties. In certain aspects, oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Other embodiments include O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkenyl, alkenyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. In one aspect, a modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. Other modifications include 2'-dimethylaminoethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-

CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub>, also described in examples hereinbelow.

**[0105]** Still other modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), 2'-allyl (2'-CH<sub>2</sub>-CH=CH<sub>2</sub>), 2'-O-allyl (2'-O-CH<sub>2</sub>-CH=CH<sub>2</sub>) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. In one aspect, a 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, for example, at the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. See, for example, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, the disclosures of which are incorporated by reference in their entireties herein.

**[0106]** In one aspect, a modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is in certain aspects is a methylene (-CH<sub>2</sub>-)<sub>n</sub> group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

### Natural and Modified Bases

**[0107]** Oligonucleotides may also include base modifications or substitutions. As used herein, "unmodified" or "natural" bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified bases include other synthetic and natural bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified bases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzox-azin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified bases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further bases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these bases are useful for increasing the binding affinity and include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. and are, in certain aspects combined with 2'-O-methoxyethyl sugar modifications. See, U.S. Pat. Nos. 3,687,808, U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,750,692 and 5,681,941, the disclosures of which are incorporated herein by reference.

**[0108]** A "modified base" or other similar term refers to a composition which can pair with a natural base (e.g., adenine, guanine, cytosine, uracil, and/or thymine) and/or can pair with a non-naturally occurring base. In certain aspects, the modified base provides a T<sub>m</sub> differential of 15, 12, 10, 8, 6, 4, or 2°C. or less. Exemplary modified bases are described in EP 1 072 679 and WO 97/12896.

**[0109]** By "nucleobase" is meant the naturally occurring nucleobases adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U) as well as non-naturally occurring nucleobases such as xanthine, diaminopurine, 8-oxo-N<sup>6</sup>-methyladenine, 7-deazaxanthine, 7-deazaguanine, N<sup>4</sup>,N<sup>4</sup>-ethanocytosine, N',N'-ethano-2,6-diaminopurine, 5-methylcytosine (mC), 5-(C<sup>3</sup>-C<sup>6</sup>)-alkynyl-cytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanine, inosine and the "non-naturally occurring" nucleobases described in Benner et al., U.S. Pat. No. 5,432,272 and Susan M. Freier and Karl-Heinz Altmann, Nucleic Acids Research, 1997, vol. 25, pp 4429-4443. The term "nucleobase" thus includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof. Further naturally and non-naturally occurring nucleobases include those disclosed in U.S. Pat. No. 3,687,808 (Merigan, et al.), in Chapter 15 by Sanghvi, in Antisense Research and Application, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613-722 (see especially pages 622 and 623, and in the Concise Encyclopedia of Polymer Science and Engineering, J. I. Kroschwitz



Ed., John Wiley & Sons, 1990, pages 858-859, Cook, Anti-Cancer Drug Design 1991, 6, 585-607). The term "nucleosidic base" or "base unit" is further intended to include compounds such as heterocyclic compounds that can serve like nucleobases including certain "universal bases" that are not nucleosidic bases in the most classical sense but serve as nucleosidic bases. Especially mentioned as universal bases are 3-nitropyrrole, optionally substituted indoles (e.g., 5-nitroindole), and optionally substituted hypoxanthine. Other desirable universal bases include, pyrrole, diazole or triazole derivatives, including those universal bases known in the art.

### Conjugates

**[0110]** Another modification of the oligonucleotides contemplated involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups contemplated include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligonucleotides, and groups that enhance the pharmacokinetic properties of oligonucleotides. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Also contemplated are groups that enhance binding or association of the oligonucleotide or a targeting agent to its target (either the target polynucleotide or target of the targeting agent) by bringing either or both into proximity of the target through association or interaction with the actin/myosin intracellular framework, the early to late endosome framework, the translational to endoplasmic reticulum to golgi network pathway, etc.).

**[0111]** Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, the entire disclosures of which are incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxysterol moiety. Oligonucleotides may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folic acid, a benzothiadiazide, chlorothiazide, a diazepam, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in U.S. patent application Ser. No. 09/334,130 (filed Jun. 15, 1999) which is incorporated herein by reference in its entirety. See, for example U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

**[0112]** Still other conjugate moieties include proteins, peptides, and peptide mimetics. In one aspect, members from this group of moieties are selected based on their binding specificity to a ligand expressed in or on a target cell type or a target organ. Alternatively, moieties of this type include a receptor for a ligand on a target cell (instead of the ligand itself), and in still other aspects, both a receptor and its ligand are contemplated in those instances wherein a target cell expresses both the receptor and the ligand. In other aspects, members from this group are selected based on their biological activity, including for example enzymatic activity, agonist properties, antagonist properties, multimerization capacity (including homo-multimers and hetero-multimers). With regard to proteins, conjugate moieties contemplated include full length protein and fragments thereof which retain the desired property of the full length proteins. Fusion proteins, including fusion proteins wherein one fusion component is a fragment or a mimetic, are also contemplated. This group also includes antibodies along with fragments and derivatives thereof, including but not limited to Fab' fragments, F(ab)<sub>2</sub> fragments, Fv fragments, Fc fragments, one or more complementarity determining regions (CDR) fragments, individual heavy chains, individual light chain, dimeric heavy and light chains (as opposed to heterotetrameric heavy and light chains found in an intact antibody, single chain antibodies (scAb), humanized antibodies (as well as antibodies modified in the manner of humanized antibodies but with the resulting antibody more closely resembling an antibody in a non-human species), chelating recombinant antibodies (CRABs), bispecific antibodies and multispecific antibodies, and other antibody derivative or fragments known in the art.

Chimerics

**[0113]** It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. These "chimeric" antisense compounds typically contain at least one region including a modification as described herein, while the remainder of the oligonucleotide remains "unmodified."

**[0114]** In certain aspects, the modification confers increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. In other aspects the modification serves as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNaseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

**[0115]** Chimeric compounds may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. See, for example, U.S. Pat. No. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922.

TARGET POLYNUCLEOTIDES

**[0116]** In various aspects, the target polynucleotide is either eukaryotic, prokaryotic, or viral.

**[0117]** In various embodiments, methods provided include those wherein the target polynucleotide is a mRNA encoding a gene product and translation of the gene product is inhibited, or the target polynucleotide is DNA in a gene encoding a gene product and transcription of the gene product is inhibited. In methods wherein the target polynucleotide is DNA, the polynucleotide is in certain aspects DNA which encodes the gene product being inhibited. In other methods, the DNA is complementary to a coding region for the gene product. In still other aspects, the DNA encodes a regulatory element necessary for expression of the gene product. "Regulatory elements" include, but are not limited to enhancers, promoters, silencers, polyadenylation signals, regulatory protein binding elements, regulatory introns, ribosome entry sites, and the like. In still another aspect, the target polynucleotide is a sequence which is required for endogenous replication.

**[0118]** The terms "start codon region" and "translation initiation codon region" refer to a portion of an mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions which may be targeted effectively with the oligonucleotides on the functionalized nanoparticles.

**[0119]** Other target regions include the 5' untranslated region (5'UTR), the portion of an mRNA in the 5' direction from the translation initiation codon, including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3' untranslated region (3'UTR), the portion of an mRNA in the 3' direction from the translation termination codon, including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site.

**[0120]** For prokaryotic target polynucleotides, in various aspects, the polynucleotide is genomic DNA or RNA transcribed from genomic DNA. For eukaryotic target polynucleotides, the polynucleotide is an animal polynucleotide, a plant polynucleotide, a fungal polynucleotide, including yeast polynucleotides,.. As above, the target polynucleotide is either a genomic DNA or RNA transcribed from a genomic DNA sequence. In certain aspects, the target polynucleotide is a mitochondrial polynucleotide. For viral target polynucleotides, the polynucleotide is viral genomic RNA, viral genomic DNA, or RNA transcribed from viral genomic DNA.

DESIRED INHIBITION RESULTS

**[0121]** Methods for inhibiting gene product expression provided include those wherein expression of the target gene product is inhibited by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%,

at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% compared to gene product expression in the absence of an oligonucleotide-functionalized nanoparticle. In other words, methods provided embrace those which results in essentially any degree of inhibition of expression of a target gene product.

[0122] The degree of inhibition is determined in vivo from a body fluid sample or from a biopsy sample or by imaging techniques well known in the art. Alternatively, the degree of inhibition is determined in a cell culture assay, generally as a predictable measure of a degree of inhibition that can be expected in vivo resulting from use of a specific type of nanoparticle and a specific oligonucleotide.

## KITS

[0123] Also provided are kits for inhibiting gene expression from a target polynucleotide. In one embodiment, the kit comprises at least one container, the container holding at least one types of nanoparticles as described herein having one or more oligonucleotides as described here attached thereto. The oligonucleotides on the first type of nanoparticles have one or more sequences complementary (or sufficiently complementary as disclosed herein) to one or more sequences of a first portion of a target polynucleotide. The container optionally includes one or more additional type of nanoparticles which have a sequence complementary to one or more sequence of a second portion of the target polynucleotide.

[0124] In another embodiment, the kit comprises at least two containers. The first container holds one or more nanoparticles as disclosed herein having one or more oligonucleotides as described herein attached thereto which have a sequence complementary to one or more sequence of a portion of a target polynucleotide. The second container holds one or more nanoparticles having one or more oligonucleotides attached thereto which have a sequence complementary to one or more sequences of the same or a different portion of the target polynucleotide.

[0125] In another embodiment, the kits have oligonucleotides and nanoparticles in separate containers, and the oligonucleotides are to attached to the nanoparticles prior to use for inhibiting gene expression. In one aspect, the oligonucleotides and/or the nanoparticles are functionalized so that the oligonucleotides can be attached to the nanoparticles. Alternatively, the oligonucleotides and/or nanoparticles are provided in the kit without functional groups, in which case they must be functionalized prior to performing the assay.

[0126] In various aspects of the kits provided, oligonucleotides include a label or the kit includes a label which can be attached to the oligonucleotides. Alternatively, the kits include labeled nanoparticles or labels which can be attached to the nanoparticles. In each embodiment, the kit optionally includes instructions, each container contains a label, the kit itself includes a label, the kit optionally includes one or more non-specific oligonucleotides (either attached to nanoparticles or not attached to nanoparticles).

## **EXAMPLES**

### **Example 1**

#### **Preparation of Gold Nanoparticles**

[0127] Citrate-stabilized 13nm gold nanoparticles were prepared by reduction of  $\text{HAuCl}_4$  with citrate as described in Frens, Nature Phys. Sci., 241, 20 (1973) and Grabar, Anal. Chem., 67, 735 (1995). Briefly, all glassware was cleaned in aqua regia (3 parts HCl, 1 part  $\text{HNO}_3$ ), rinsed with Nanopure  $\text{H}_2\text{O}$ , then oven dried prior to use.  $\text{HAuCl}_4$  and sodium citrate were purchased from Aldrich Chemical Company. An aqueous solution of  $\text{HAuCl}_4$  (1 mM, 500 mL) was brought to a reflux while stirring, and then 50 mL of a 38.8 mM trisodium citrate solution was added quickly, resulting in a change in solution color from pale yellow to deep red. After the color change, the solution was refluxed for an additional fifteen minutes, allowed to cool to room temperature, and subsequently filtered through a Micron Separations Inc. 0.45 micron nylon filter. Au colloids were characterized by UV-vis spectroscopy using a Hewlett Packard 8452A diode array spectrophotometer and by Transmission Electron Microscopy (TEM) using a Hitachi 8100 transmission electron microscope. A solution of 13 nm diameter gold particles exhibits a characteristic surface plasmon band centered at 518 - 520 nm. that is useful in verifying the preparation of these particles.

### **Example 2**

[0128] To probe the general uptake of antisense oligonucleotide-modified gold nanoparticle agents (ASNPs) in cells, a mouse cell line (C-166) and two human cancer models (HeLa and A594) were examined. These cell lines were chosen to represent different species and inherent differences between cell and tissue types. Sterile filtered ASNPs were added

directly to the cell culture media of adherent cells in concentrations ranging from 1 to 60 nM. Forty-eight hours after nanoparticle addition, the cells were washed 3 times in PBS buffer, collected, and counted using a Guava EasyCyte flow cytometer (Guava Technologies). To prepare samples for inductively coupled plasma mass spectrometry (ICP-MS) (Thermo-Fisher), the cells were dissolved with neat nitric acid at 60°C overnight. The Au content of the cell digest was determined by ICP-MS. Each cell sample was prepared in a matrix consisting of 3% HNO<sub>3</sub>, 5 ppb Indium (internal standard), and Nanopure™ water. In order to extract the number of nanoparticles taken up by each cell, the number of nanoparticles must be calculated based on the concentration of Au found in the sample. This was done using the molecular weight of Au and the diameter of the nanoparticle to calculate Au atoms per particle ( $6.78 \times 10^4$  atoms/particle). Once the number of particles was calculated, this particle number was divided by the cell count to determine the number of ASNPs per cell. Cell samples treated briefly (10 minutes) with ASNPs were prepared as above and used as controls for background subtraction in the case of ICP measurements to correct for any "sticking" of the nanoparticles to the cells and culture vessels during harvesting and preparation, or background ICP counts. All ICP experiments were performed in triplicate and values obtained were averaged. To test the validity of calculated nanoparticle values, we analyzed Au NP solutions with known concentrations (Ted Pella, Inc.,  $7 \times 10^{11}$  particles/mL, 1.16 nM). Gold samples were centrifuged (13,000 rpm, 30 min) and then re-suspended in 25  $\mu$ L of KCN (0.1M) for 3 hours to completely dissolve the particles. Concentrations of 290 pM, 120 pM, 29 pM, 12 pM, 4.6 pM, 1.8 pM, 500 fM, were analyzed by ICP-MS. Calculated values were similar to manufacturer concentrations (22.1% standard error). The results of these experiments demonstrate that while the uptake of ASNPs is universal across multiple cell types, the absolute number of nanoparticles varies by cell type by as much as a factor of 20 (Figure 1).

**[0129]** The amount of ASNPs found in each cell is proportional to the concentration of particles added to the media over the range of concentrations tested. Specifically, at low concentrations uptake varies by concentration in a linear manner, until a saturation point is reached at the highest concentrations tested (Figure 1). Additionally, the total number of ASNPs determined to enter or associate with each cell type is remarkably high, reaching up to  $3 \times 10^7$  nanoparticles per cell in C166 cells. Similarly, the maximum number of ASNPs is  $1 \times 10^7$  and  $1 \times 10^6$  nanoparticles per cell in HeLa and A549 cells, respectively. For comparison purposes, others have observed from one thousand to five thousand nanoparticles per cell in an analogous cell-line for Au NPs that are not functionalized with DNA (Chithrani et al., 2007, Nano Lett. 7(6): 1542-1550). These experiments used a similar collection, washing, and mass-based quantification process, and underscore the importance of oligonucleotide functionalization.

### Example 3

**[0130]** Since the number of ASNPs associated with each cell was found to be higher than reported values for other modified Au NP systems, it was hypothesized that the oligonucleotides were strongly contributing to cellular uptake. To probe this contribution, particles with varying numbers of oligonucleotides were prepared by co-functionalizing them with OEG thiol diluent (Figure 2A). OEG was chosen due to its charge neutrality, water solubility, and its ability to passivate surfaces in a manner that resists adsorption of biological molecules (Prime et al., 1991 Science 252(5009): 1164-1167). It should be noted that diluent molecules must be included in order to keep the Au NP surface fully passivated and the particles stable. This OEG diluent allowed ASNPs to be synthesized with zero to  $80 \pm 2$  oligonucleotides per particle that were stable under all the conditions required for cell culture. The stoichiometry during the functionalization process was varied to produce a range of DNA loadings (Figure 2A).

**[0131]** Quantification of the cellular uptake of these mixed monolayer particles demonstrated that these values are highly dependent on the number of oligonucleotides immobilized on each ASNP. For example, with the A549 cell line (Figure 2B), which is qualitatively representative of the behavior of the C166 and HeLa cells, particles with lower oligonucleotide loadings are not readily internalized by cells. However, at loadings of 60 strands per particle cellular association reaches a maximum of approximately  $1.3 \times 10^6$  ASNPs/cell, and does not appreciably increase at higher oligonucleotide density. For comparison purposes, OEG-functionalized particles without oligonucleotides were also prepared and investigated under identical experimental conditions. While still exhibiting uptake, (thousands of nanoparticles per cell) even at the highest (36 nM) concentrations examined, the uptake of fully OEG-functionalized particles were significantly lower than the ASNP particles ( $10^3$  lower uptake) (Figure 2C).

**[0132]** In addition to quantitative measurements, we also investigated the size and surface potential of the particles before and after exposure to cell culture conditions to gain insight into how they were interacting with the extracellular environment. Dynamic light scattering (DLS) measurements were performed to estimate the initial measured hydrodynamic radius of the ASNPs. DLS data show that the average diameter of an ASNP functionalized with only DNA (approximately 80 strands; 13 nm Au NP) is  $42 \pm 1$  nm while that of a fully OEG-functionalized particle is  $27 \pm 1$  nm. Interestingly, the average size of the DNA-functionalized particles increases to  $76 \pm 3$  nm upon exposure to cell culture media, while the size of the OEG functionalized particle remains relatively constant (Table 1). This observation suggests that in cell culture media alone, some components are attracted to the ASNPs, which results in an increase in size.

Table 1: ASNP characteristics before and after media exposure.

Oligonucleotide Strands/ AuNP	Diameter (nm)		Surface potential (mV)		Adsorbed proteins/ ASNP
	before media	after media	before media	after media	
79±2	42 ±1	76 ±3	-21 ±4	-13 ±1	23 ±3
32±1	56 ±2	77 ±2	-36 ±2	-24 ± 2	14 ± 1
7±1	38 ±1	50 ±2	-34 ±2	-27 ± 1	10 ± 1
0	27 ±1	30 ±1	-20 ±1	-19 ± 1	2 ± 3

**[0133]** Zeta potential measurements indicate a change in surface potential that accompanies the size change of the ASNP, which we hypothesize is due to positively charged serum proteins binding to the DNA shell on the Au NPs (Table 1). Initially, the surface potential of the ASNPs in non-serum containing media was  $-21 \pm 4$  mV. After exposure to media containing proteins, the ASNPs became more positively charged at  $-13 \pm 1$  mV. In contrast, Au NPs functionalized with OEG did not show a change in surface potential after exposure to serum containing media. While ASNPs appear to become associated with serum proteins, the OEG particles do not. This is consistent with the well-characterized passivation properties of OEG monolayers with respect to protein adsorption (Prime et al., 1991 Science 252(5009): 1164-1167).

**[0134]** Further analysis using a fluorescence-based assay for protein quantification was carried out and confirmed that the observed size and surface potential changes were due to protein adsorption on the ASNP surface. Additionally, this assay allowed for an estimate of the number of proteins that are attached to each particle. ASNPs (final concentration 6 nM) were incubated both in serum-containing media and serum-free media for 24 hrs at 37° C. After this treatment, ASNPs were isolated from solution via three consecutive centrifugation steps (13,000 rpm, 20 min) and washed with PBS buffer to remove unbound proteins, and finally the Au NPs were dissolved with KCN (2.5 mM final concentration). A Quant-iT fluorescence protein assay (Invitrogen) was used to determine the relative number of proteins in the solution. Estimation of the number of bound proteins per ASNP was calculated using a standard curve and an assumed average protein size of 60kD. In the case of a fully DNA-functionalized Au NP (80 strands per 13 nm particle), approximately 23 proteins remain attached to each particle after separation from the media (assuming an average protein is 60kD). As the number of oligonucleotides per particle decreases, so does the number of proteins per particle (Table 1). These numbers may be interpreted as minimum values, as the washing process to remove unbound proteins could remove weakly bound proteins from the ASNPs. Nonetheless, the assay allows for comparison of particles functionalized with varying numbers of oligonucleotides, and it confirms that the density of oligonucleotides directly correlates with the number of proteins, providing one possible reason for the increasing numbers of ASNPs as a function of the DNA loading in the case of particles exposed to cell culture media. While others have looked at the contribution of non-specific serum proteins to the uptake of citrate stabilized Au NPs (Chithrani et al., 2006 Nano Letters 6(4): 662-668), the number of proteins as a determining factor in the uptake of Au NPs has not yet been established. Data presented herein show that specific surface modification by oligonucleotides can be used to control the number of proteins and hence control cellular interactions of Au NP agents and perhaps materials in general. The measurements demonstrate that the quantity of ASNPs associated with each cell is significant, and orders of magnitude larger than what has been observed for non-functionalized, protein or peptide-modified Au NPs (Liu et al., 2007 Analytical Chemistry 79(6): 2221-2229).

**[0135]** In summary, based on literature precedent and the negative charge presented by the DNA functionalization, this uptake ability would not be anticipated. To test the contribution of the oligonucleotides present on the nanoparticle surface to their cellular uptake, the density of oligonucleotides on the surface was varied using OEG as a diluent. Even at high concentrations, it was found that Au NPs functionalized with only OEG showed comparatively little internalization by the cell models studied. The data indicate that the number of proteins increases with the number of oligonucleotides on the surface, reaching a maximum of 23. proteins/particle. Further, their subsequent uptake correlates well with the number of absorbed proteins. The uptake plateau at 60 oligonucleotides per particle is perhaps due to a saturation of proteins on the surface of the oligonucleotide layer. Beyond this point, additional oligonucleotides may confer no additional ability to recruit proteins. Compared to other particles and traditional transfection agents, the differences in uptake of ASNPs may be due to both the number and nature of the proteins which are attracted to the oligonucleotides on the ASNPs.

**[0136]** Thus, in the co-functionalized particles the oligonucleotides provide the contribution to cellular internalization. By increasing the number of oligonucleotides, increased uptake of the ASNPs was observed, with a maximum uptake reached at loadings of approximately 60 oligonucleotides per Au NP. These data show that the surface density of oligonucleotides mediate the amount of nanoparticles internalized by cells.

**Example 4**

**[0137]** As proof of the oligonucleotide-modified gold nanoparticle for drug control concept, the anticancer drug doxorubicin hydrochloride (dox) in a lung cancer cell model (A549) was investigated. Cultures treated with dox-containing cell culture media were observed that displayed a significant decrease in cell viability (cells are approximately 60% viable at 25  $\mu$ M dox concentration) as a result of the systemic toxicity of this anticancer drug. However, when an oligonucleotide functionalized nanoparticle agent containing a non-specific sequence is added to the culture at the same point as the drug molecule, a dose-dependant recovery of cell viability is observed (cells recover to approximately 80% viable at 3 nM concentration of nanoparticles). The dox-treated cells were then examined in the presence of an anti-survivin oligonucleotide modified gold nanoparticle conjugate. Anti-survivin oligonucleotides have been shown to sensitize cells to chemotherapeutic agents. In these studies, the anti-survivin containing nanoparticle agent added to the culture at the same point as the drug molecule reduce cell viability to 45% at low concentrations and recover cell viability to 75% at high concentrations (Figure 3). These examples demonstrate that oligonucleotide-modified nanoparticles can be used to control the efficacy of delivered drugs.

**[0138]** These experiments demonstrate that oligonucleotide-modified nanoparticle agents can be used to modulate drug effects. In the case of a nonspecific oligonucleotide modified nanoparticle agent, the agent interacts strongly with the drug molecule, and alters the normal mechanism by which the drug enters the cells. In the case of the anti-survivin oligonucleotide modified nanoparticle agent, it is probable that the agent interacts with the drug molecules at high concentrations. At low particle agent concentrations however, excess dox weakens the cell, and anti-survivin particles make the drug more effective.

**Example 5**

**[0139]** To probe the intracellular distribution of the dox, confocal fluorescence imaging experiments were carried out to visualize the fluorescent dox molecules in the cells. Imaging studies indicate that oligonucleotide-modified nanoparticles change the cellular-distribution of dox. Cells treated with dox alone have the majority of the fluorescent drug molecule in their nucleus, while cells treated with dox and a high concentration of nanoparticles have more cytoplasmic localization of the drug molecules. These experiments provide insight into the mechanism that reduces the toxic affects of this drug at high nanoparticle concentrations.

**Claims**

1. A method of modulating cellular uptake of a first functionalized nanoparticle compared to a second functionalized nanoparticle comprising the step of:

modulating packing density of an oligonucleotide functionalized on the first nanoparticle, wherein a higher packing density results in increased cellular uptake of the functionalized nanoparticle compared to the second nanoparticle functionalized at a lower packing density.

2. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 1 oligonucleotide per nanoparticle.

3. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 5 oligonucleotides per nanoparticle.

4. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 10 oligonucleotides per nanoparticle.

5. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 20 oligonucleotides per nanoparticle.

6. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 40 oligonucleotides per nanoparticle.

7. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 60 oligonucleotides per nanoparticle.

8. The method of claim 1 wherein the packing density of the oligonucleotide on the surface of the first nanoparticle is increased by at least 80 oligonucleotides per nanoparticle.

5 9. The method of claim 1 wherein uptake of the first functionalized nanoparticle is increased by at least 50% compared to the second nanoparticle.

10. The method of claim 1 wherein the uptake of the first functionalized nanoparticle is increased by at least 100% compared to the second nanoparticle.

10

### Patentansprüche

1. Verfahren zum Modulieren der zellulären Aufnahme eines ersten funktionalisierten Nanopartikels im Vergleich zu einem zweiten funktionalisierten Nanopartikel, umfassend die Schritte:

15

Modulieren der Packungsdichte eines Oligonukleotids, das auf dem ersten Nanopartikel funktionalisiert ist, wobei eine höhere Packungsdichte zu einer erhöhten zellulären Aufnahme des funktionalisierten Nanopartikels im Vergleich zu dem zweiten Nanopartikel, das mit einer niedrigeren Packungsdichte funktionalisiert ist, führt.

20

2. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 1 Oligonukleotid pro Nanopartikel erhöht ist.

25

3. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 5 Oligonukleotide pro Nanopartikel erhöht ist.

25

4. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 10 Oligonukleotide pro Nanopartikel erhöht ist.

30

5. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 20 Oligonukleotide pro Nanopartikel erhöht ist.

35

7. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 60 Oligonukleotide pro Nanopartikel erhöht ist.

40

8. Verfahren gemäß Anspruch 1, wobei die Packungsdichte des Oligonukleotids auf der Oberfläche des ersten Nanopartikels um wenigstens 80 Oligonukleotide pro Nanopartikel erhöht ist.

9. Verfahren gemäß Anspruch 1, wobei die Aufnahme des ersten funktionalisierten Nanopartikels um wenigstens 50 % im Vergleich zu dem zweiten Nanopartikel erhöht ist.

45

10. Verfahren gemäß Anspruch 1, wobei die Aufnahme des ersten funktionalisierten Nanopartikels um wenigstens 100 % im Vergleich zu dem zweiten Nanopartikel erhöht ist.

### Revendications

50 1. Procédé de modulation de l'absorption cellulaire d'une première nanoparticule fonctionnalisée par comparaison avec une seconde nanoparticule fonctionnalisée comprenant l'étape consistant à :

moduler la densité d'occupation d'un oligonucléotide fonctionnalisé sur la première nanoparticule, une densité d'occupation plus élevée ayant pour résultat une absorption cellulaire accrue de la nanoparticule fonctionnalisée par comparaison avec la seconde nanoparticule fonctionnalisée à une densité d'occupation inférieure.

55

2. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 1 oligonucléotide par nanoparticule.

## EP 2 160 464 B1

3. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 5 oligonucléotides par nanoparticule.
- 5 4. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 10 oligonucléotides par nanoparticule.
5. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 20 oligonucléotides par nanoparticule.
- 10 6. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 40 oligonucléotides par nanoparticule.
7. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 60 oligonucléotides par nanoparticule.
- 15 8. Procédé selon la revendication 1 dans lequel la densité d'occupation de l'oligonucléotide sur la surface de la première nanoparticule est accrue d'au moins 80 oligonucléotides par nanoparticule.
- 20 9. Procédé selon la revendication 1 dans lequel l'absorption de la première nanoparticule fonctionnalisée est accrue d'au moins 50 % par comparaison avec la seconde nanoparticule.
10. Procédé selon la revendication 1 dans lequel l'absorption de la première nanoparticule fonctionnalisée est accrue d'au moins 100 % par comparaison avec la seconde nanoparticule.

25

30

35

40

45

50

55






Figure 1

**Figure 1.** Cellular uptake of ASNPs. Analysis of ASNPs in three different cell types (HeLa, C166, A549) shows that the number of ASNPs per cell is dependent on initial particle concentration and cell type.




Figure 2

**Figure 2.** A) Characterization of oligonucleotide loading on OEG:DNA particles. B) Uptake as a function of the number of oligonucleotides per ASNP in A549 cells. The number of ASNPs per cell increases as the number of oligonucleotides increases (particle concentration in the media was 10 nM). C) Au NPs functionalized with OEG show comparatively little uptake (A549 cells) even at high concentration additions.




Figure 3

**Figure 3.** Plots of cell viability as a function of nanoparticle concentration of dox-treated cell cultures. Dox-treated controls are circled in blue. In the case of a non-specific oligonucleotide-modified nanoparticle a dose-dependant recovery of viability is observed (left panel). In the case of an anti-survivin nanoparticle (a sequence known to chemosensitize cells) an initial decrease in viability followed by a sharp recovery is observed. The lines are drawn as a guide to the eye.

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 20030147966 A [0028] [0044] [0049] [0050]
- US 03445102 A [0046]
- US 0150825 W [0046]
- US 4489055 A [0047]
- US 20050214782 A [0057]
- US 20060019917 A [0059]
- US 20060008907 A [0059]
- US 20050059016 A [0059]
- US 20050197315 A [0059]
- US 5472881 A [0068]
- US 760500 A [0069]
- US 09820279 A [0069]
- US 0101190 W [0069] [0071]
- US 0110071 W [0069] [0071]
- US 34466799 A [0071]
- US 09603830 B [0071]
- US 09760500 B [0071]
- US 09820279 B [0071]
- US 09927777 B [0071]
- US 9712783 W [0071]
- US 0017507 W [0071]
- WO 8902439 A, Arnold [0093]
- WO 9506731 A, Usman [0093]
- WO 9511910 A, Dudycz [0093]
- US 4289872 A, Denkenwalter [0094]
- US 5229490 A, Tam [0094]
- WO 9321259 A, Frechet [0094]
- US 4640835 A [0094]
- US 4496689 A [0094]
- US 4301144 A [0094]
- US 4670417 A [0094]
- US 4791192 A [0094]
- US 4179337 A [0094]
- US 3687808 A [0098] [0107] [0109]
- US 4469863 A [0098]
- US 4476301 A [0098]
- US 5023243 A [0098]
- US 5177196 A [0098]
- US 5188897 A [0098]
- US 5264423 A [0098]
- US 5276019 A [0098]
- US 5278302 A [0098]
- US 5286717 A [0098]
- US 5321131 A [0098]
- US 5399676 A [0098]
- US 5405939 A [0098]
- US 5453496 A [0098]
- US 5455233 A [0098]
- US 5466677 A [0098] [0099]
- US 5476925 A [0098]
- US 5519126 A [0098]
- US 5536821 A [0098]
- US 5541306 A [0098]
- US 5550111 A [0098]
- US 5563253 A [0098]
- US 5571799 A [0098]
- US 5587361 A [0098]
- US 5194599 A [0098]
- US 5565555 A [0098]
- US 5527899 A [0098]
- US 5721218 A [0098]
- US 5672697 A [0098]
- US 5625050 A [0098]
- US 5034506 A [0099] [0101]
- US 5166315 A [0099]
- US 5185444 A [0099]
- US 5214134 A [0099]
- US 5216141 A [0099]
- US 5235033 A [0099]
- US 5264562 A [0099]
- US 5264564 A [0099]
- US 5405938 A [0099]
- US 5434257 A [0099]
- US 5470967 A [0099]
- US 5489677 A [0099] [0101]
- US 5541307 A [0099]
- US 5561225 A [0099]
- US 5596086 A [0099]
- US 5602240 A [0099] [0101]
- US 5610289 A [0099]
- US 5608046 A [0099] [0111]
- US 5618704 A [0099]
- US 5623070 A [0099]
- US 5663312 A [0099]
- US 5633360 A [0099]
- US 5677437 A [0099]
- US 5792608 A [0099]
- US 5646269 A [0099]
- US 5677439 A [0099]
- US 5539082 A [0100]
- US 5714331 A [0100]
- US 5719262 A [0100]
- US 20040219565 A [0103]
- US 4981957 A [0105]
- US 5118800 A [0105]
- US 5319080 A [0105]
- US 5359044 A [0105]
- US 5393878 A [0105]

## EP 2 160 464 B1

- US 5446137 A [0105]
- US 5466786 A [0105]
- US 5514785 A [0105] [0111]
- US 5519134 A [0105]
- US 5567811 A [0105]
- US 5576427 A [0105]
- US 5591722 A [0105]
- US 5597909 A [0105]
- US 5610300 A [0105]
- US 5627053 A [0105]
- US 5639873 A [0105]
- US 5646265 A [0105]
- US 5658873 A [0105]
- US 5670633 A [0105]
- US 5792747 A [0105]
- US 5700920 A [0105]
- WO 9839352 A [0106]
- WO 9914226 A [0106]
- US 4845205 A [0107]
- US 5130302 A [0107]
- US 5134066 A [0107]
- US 5175273 A [0107]
- US 5367066 A [0107]
- US 5432272 A [0107] [0109]
- US 5457187 A [0107]
- US 5459255 A [0107]
- US 5484908 A [0107]
- US 5502177 A [0107]
- US 5525711 A [0107]
- US 5552540 A [0107]
- US 5587469 A [0107]
- US 5594121 A [0107]
- US 5596091 A [0107]
- US 5614617 A [0107]
- US 5645985 A [0107]
- US 5830653 A [0107]
- US 5763588 A [0107]
- US 6005096 A [0107]
- US 5750692 A [0107]
- US 5681941 A [0107]
- EP 1072679 A [0108]
- WO 9712896 A [0108]
- US 9209196 W [0111]
- US 6287860 B [0111]
- US 33413099 A [0111]
- US 4828979 A [0111]
- US 4948882 A [0111]
- US 5218105 A [0111]
- US 5525465 A [0111]
- US 5541313 A [0111]
- US 5545730 A [0111]
- US 5552538 A [0111]
- US 5578717 A [0111]
- US 5580731 A [0111]
- US 5591584 A [0111]
- US 5109124 A [0111]
- US 5118802 A [0111]
- US 5138045 A [0111]
- US 5414077 A [0111]
- US 5486603 A [0111]
- US 5512439 A [0111]
- US 5578718 A [0111]
- US 4587044 A [0111]
- US 4605735 A [0111]
- US 4667025 A [0111]
- US 4762779 A [0111]
- US 4789737 A [0111]
- US 4824941 A [0111]
- US 4835263 A [0111]
- US 4876335 A [0111]
- US 4904582 A [0111]
- US 4958013 A [0111]
- US 5082830 A [0111]
- US 5112963 A [0111]
- US 5214136 A [0111]
- US 5245022 A [0111]
- US 5254469 A [0111]
- US 5258506 A [0111]
- US 5262536 A [0111]
- US 5272250 A [0111]
- US 5292873 A [0111]
- US 5317098 A [0111]
- US 5371241 A [0111]
- US 5391723 A [0111]
- US 5416203 A [0111]
- US 5451463 A [0111]
- US 5510475 A [0111]
- US 5512667 A [0111]
- US 5565552 A [0111]
- US 5567810 A [0111]
- US 5574142 A [0111]
- US 5585481 A [0111]
- US 5587371 A [0111]
- US 5595726 A [0111]
- US 5597696 A [0111]
- US 5599923 A [0111]
- US 5599928 A [0111]
- US 5688941 A [0111]
- US 5013830 A [0115]
- US 5149797 A [0115]
- US 5220007 A [0115]
- US 5256775 A [0115]
- US 5366878 A [0115]
- US 5403711 A [0115]
- US 5491133 A [0115]
- US 5565350 A [0115]
- US 5623065 A [0115]
- US 5652355 A [0115]
- US 5652356 A [0115]
- US 5700922 A [0115]

## Non-patent literature cited in the description

- **PATIL et al.** *AAPS Jour*, 2005, vol. 7, E61 [0001]
- **MCMANUS et al.** *Nat. Rev. Genet.*, 2002, vol. 3, 737 [0001]
- **LEBEDEVA et al.** *Annu. Rev. Pharmacol. Toxicol.*, 2001, vol. 41, 403 [0001]
- **JASON et al.** *Toxic. And Appl. Pharm.*, 2004, vol. 201, 66 [0001]
- **STEPHENSON et al.** *Proc. Not. Acad. Sci. U.S.A.*, 1978, vol. 75, 285 [0001]
- **ZAMECNIK et al.** *Proc. Nat. Acad. Sci. U.S.A.*, 1978, vol. 75, 280 [0001]
- **BHARALI et al.** *Proc. Nat. Acad. Sci. U.S.A.*, 2005, vol. 102, 11539 [0001]
- **BIELINSKA et al.** *Bioconjugate Chem.*, 1999, vol. 10, 843 [0001]
- **DE MESMAEKER et al.** *Acc. Chem. Res.*, 1995, vol. 28, 366 [0002]
- **MYERS et al.** *Org. Lett.*, 2003, vol. 5, 2695 [0002]
- **DANIEL et al.** *Chem. Rev.*, 2004, vol. 104, 293 [0027]
- **BAUDHUIN et al.** *Colloidal Gold: Principles, Methods, and Applications*, 1989, vol. 2, 1 [0027]
- **TKACHENKO et al.** *Bioconjugate Chem.*, 2004, vol. 15, 482 [0027]
- **THOMAS et al.** *Proc. Nat. Acad. Sci.*, 2003, vol. 100, 9138 [0027]
- **SUNDARAM et al.** *Nucl. Acids Res.*, 1999, vol. 24, 1375 [0027]
- **SANDHU et al.** *Bioconjugate Chem.*, 2002, vol. 13, 3 [0027]
- **SULLIVAN et al.** *Gene Therapy*, 2003, vol. 10, 1882 [0027]
- **JEN et al.** *Langmuir*, 2004, vol. 20, 1369 [0027]
- **MIRKIN et al.** *Nature*, 1996, vol. 382, 607 [0027]
- **LYTTON-JEAN et al.** *J Am. Chem. Soc.*, 2005, vol. 127, 12754 [0027]
- **ROSI et al.** *Chem. Rev.*, 2005, vol. 105, 1547 [0027]
- **ELGHANIAN et al.** *Science*, 1997, vol. 277, 1078 [0027]
- **NAM et al.** *Science*, 2003, vol. 301, 1884 [0027]
- **HE et al.** *J Am. Chem. Soc.*, 2000, vol. 122, 9071 [0027]
- **MAXWELL et al.** *J Am. Chem. Soc.*, 2002, vol. 124, 9606 [0027]
- **WELLER.** *Angew. Chem. Int. Ed. Engl.*, 1993, vol. 32, 41 [0045]
- **HENGLEIN.** *Top. Curr. Chem.*, 1988, vol. 143, 113 [0045]
- **HENGLEIN.** *Chem. Rev.*, 1989, vol. 89, 1861 [0045]
- **BRUS.** *Appl. Phys. A.*, 1991, vol. 53, 465 [0045]
- **BAHNCMANN.** *Photochemical Conversion and Storage of Solar Energy*. 1991, 251 [0045]
- **WANG ; HERRON.** *J. Phys. Chem.*, 1991, vol. 95, 525 [0045]
- **OLSHAVSKY et al.** *J. Am. Chem. Soc.*, 1990, vol. 112, 9438 [0045]
- **USHIDA et al.** *J. Phys. Chem.*, 1992, vol. 95, 5382 [0045]
- **Clusters and Colloid.** VCH, 1994 [0047]
- **Colloidal Gold: Principles, Methods, and Applications.** Academic Press, 1991 [0047]
- **MASSART, R.** *IEEE Transactions On Magnetics*, 1981, vol. 17, 1247 [0047]
- **AHMADI, T. S. et al.** *Science*, 1996, vol. 272, 1924 [0047]
- **HENGLEIN, A. et al.** *J. Phys. Chem.*, 1995, vol. 99, 14129 [0047]
- **CURTIS, A. C. et al.** *Angew. Chem. Int. Ed. Engl.*, 1988, vol. 27, 1530 [0047]
- **FATTAL et al.** *J. Controlled Release*, 1998, vol. 53, 137-143 [0047]
- **LIU et al.** *J. Am. Chem. Soc.*, 2004, vol. 126, 7422-7423 [0047]
- **TONDELLI et al.** *Nucl. Acids Res.*, 1998, vol. 26, 5425-5431 [0047]
- **KUKOWSKA-LATALLO et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 4897-4902 [0047]
- **HAVASHI.** *Vac. Sci. Technol*, July 1987, vol. A5 (4), 1375-84 [0049]
- **HAYASHI.** *Physics Today*, December 1987, 44-60 [0049]
- *MRS Bulletin*, January 1990, 16-47 [0049]
- **MARINAKOS et al.** *Adv. Mater.*, 1999, vol. 11, 34-37 [0050]
- **MARINAKOS et al.** *Chem. Mater.*, 1998, vol. 10, 1214-19 [0050]
- **ENUSTUN ; TURKEVICH.** *J. Am. Chem. Soc.*, 1963, vol. 85, 3317 [0050]
- **TKACHENKO et al.** *Bioconjugate Chem*, 2004, vol. 15, 482-490 [0053]
- **TKACHENKO et al.** *Am. Chem. Soc.*, 2003, vol. 125, 4700-4701 [0053]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual*. 1989 [0056]
- *Oligonucleotides and Analogues.* Oxford University Press, 1991 [0056]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0065]
- **ZHANG ; MADDEN.** *Genome Res.*, 1997, vol. 7, 649-656 [0065]
- **WHITESIDES.** *Proceedings of the Robert A. Welch Foundation 39th Conference On Chemical Research Nanophase Chemistry*, 1995, 109-121 [0068]
- **MUCIC et al.** *Chem. Commun.*, 1996, 555-557 [0068]
- **BURWELL.** *Chemical Technology*, 1974, vol. 4, 370-377 [0068]
- **MATTEUCCI ; CARUTHERS.** *J. Am. Chem. Soc.*, 1981, vol. 103, 3185-3191 [0068]
- **GRABAR et al.** *Anal. Chem.*, vol. 67, 735-743 [0068]
- **NUZZO et al.** *J. Am. Chem. Soc.*, 1987, vol. 109, 2358 [0068]

- **ALLARA ; NUZZO.** *Langmuir*, 1985, vol. 1, 45 [0068]
- **ALLARA ; TOMPKINS.** *J. Colloid Interface Sci.*, 1974, vol. 49, 410-421 [0068]
- **ILER.** *The Chemistry Of Silica.* Wiley, 1979 [0068]
- **TIMMONS ; ZISMAN.** *J. Phys. Chem.*, 1965, vol. 69, 984-990 [0068]
- **SORIAGA ; HUBBARD.** *J. Am. Chem. Soc.*, 1982, vol. 104, 3937 [0068]
- **HUBBARD.** *Acc. Chem. Res.*, 1980, vol. 13, 177 [0068]
- **HICKMAN et al.** *J. Am. Chem. Soc.*, 1989, vol. 111, 7271 [0068]
- **MAOZ ; SAGIV.** *Langmuir*, 1987, vol. 3, 1045 [0068]
- **MAOZ ; SAGIV.** *Langmuir*, 1987, vol. 3, 1034 [0068]
- **WASSERMAN et al.** *Langmuir*, 1989, vol. 5, 1074 [0068]
- **ELTEKOVA ; ELTEKOV.** *Langmuir*, 1987, vol. 3, 951 [0068]
- **LEC et al.** *J. Phys. Chem.*, 1988, vol. 92, 2597 [0068]
- **PRIME et al.** *Science*, 1991, vol. 252 (5009), 1164-1167 [0086] [0130] [0133]
- **SEELA ; KAISER.** *Nucleic Acids Res.*, 1990, vol. 18, 6353 [0093]
- *Nucleic Acids Res.*, 1987, vol. 15, 3113 [0093]
- **CLOAD ; SCHEPARTZ.** *J. Am. Chem. Soc.*, 1991, vol. 113, 6324 [0093]
- **RICHARDSON ; SCHEPARTZ.** *J. Am. Chem. Soc.*, 1991, vol. 113, 5109 [0093]
- **MA et al.** *Nucleic Acids Res.*, 1993, vol. 21, 2585 [0093]
- *Biochemistry*, 1993, vol. 32, 1751 [0093]
- **DURAND et al.** *Nucleic Acids Res.*, 1990, vol. 18, 6353 [0093]
- **MCCURDY et al.** *Nucleosides & Nucleotides*, 1991, vol. 10, 287 [0093]
- **JSCHKE et al.** *Tetrahedron Lett.*, 1993, vol. 34, 301 [0093]
- **ONO et al.** *Biochemistry*, 1991, vol. 30, 9914 [0093]
- **FERENTZ ; VERDINE.** *J. Am. Chem. Soc.*, 1991, vol. 113, 4000 [0093]
- **NIELSEN et al.** *Science*, 1991, vol. 254, 1497-1500 [0100]
- **MESMAEKER.** *Current Opinion in Structural Biology*, 1995, vol. 5, 343-355 [0102]
- **SUSAN M. FREIER ; KARL-HEINZ ALTMANN.** *Nucleic Acids Research*, 1997, vol. 25, 4429-4443 [0102] [0109]
- **MARTIN.** *Helv. Chim. Acta*, 1995, vol. 78, 486-504 [0104]
- *The Concise Encyclopedia Of Polymer Science And Engineering.* John Wiley & Sons, 1990, 858-859 [0107]
- **ENGLISCH et al.** *Angewandte Chemie, International Edition*, 1991, vol. 30, 613 [0107]
- **SANGHVI, Y. S.** *Antisense Research and Applications.* CRC Press, 1993, 289-302 [0107]
- **SANGHVI.** *Antisense Research and Application.* CRC Press, 1993 [0109]
- **ENGLISCH et al.** *Angewandte Chemie, International Edition*, 1991, vol. 30, 613-722 [0109]
- *Concise Encyclopedia of Polymer Science and Engineering.* John Wiley & Sons, 1990, 858-859 [0109]
- **COOK.** *Anti-Cancer Drug Design*, 1991, vol. 6, 585-607 [0109]
- **FRENS.** *Nature Phys. Sci.*, 1973, vol. 241, 20 [0127]
- **GRABAR.** *Anal. Chem.*, 1995, vol. 67, 735 [0127]
- **CHITHRANI et al.** *Nano Lett*, 2007, vol. 7 (6), 1542-1550 [0129]
- **CHITHRANI et al.** *Nano Letters*, 2006, vol. 6 (4), 662-668 [0134]
- **LIU et al.** *Analytical Chemistry*, 2007, vol. 79 (6), 2221-2229 [0134]